Document:

EX-10.5

 Exhibit 10.5 

EXECUTION 
 THE DISTRICT

 2400 DISTRICT AVENUE 

BURLINGTON, MASSACHUSETTS 

OFFICE LEASE AGREEMENT 

BETWEEN 
 NEEP INVESTORS
HOLDINGS LLC, a Delaware limited liability company 
 (“LANDLORD”) 

AND 
 SCPHARMACEUTICALS
INC., a Delaware corporation 
 (“TENANT”) 

 OFFICE LEASE AGREEMENT 

THIS OFFICE LEASE AGREEMENT (this “Lease”) is made and entered into as of June 2, 2017, by and between NEEP
INVESTORS HOLDINGS LLC, a Delaware limited liability company (“Landlord”) and SCPHARMACEUTICALS INC., a Delaware corporation (“Tenant”). The following exhibits and attachments are
incorporated into and made a part of this Lease: Exhibit A-1 (Outline and Location of Premises), Exhibit A-2 (Description of Property), Exhibit B
(Expenses and Taxes), Exhibit C (Work Letter), Exhibit D (Commencement Letter), Exhibit E (Building Rules and Regulations), and Exhibit F (Additional Provisions). 

 

	1.	Basic Lease Information. 

 1.01    “Building” shall
mean the building located at 2400 District Avenue, Burlington, Massachusetts 01803. “Rentable Square Footage of the Building” is deemed to be 103,184 square feet. 

1.02    “Park” shall mean the office park in Burlington, Massachusetts containing 10 office
buildings and related improvements commonly known as The District, or such other name by which Landlord may hereafter elect to have it referred. 

1.03    “Premises” shall mean the area shown on Exhibit A-1
to this Lease. The Premises are located on the third (3rd) floor of the Building and known as Suite 310. The “Rentable Square Footage of the Premises” is deemed to be
13,066 rentable square feet. Landlord and Tenant stipulate and agree that the Rentable Square Footage of the Building, and the Rentable Square Footage of the Premises are correct. The Premises exclude Common Areas (as defined below). If the
Premises include less than the entire rentable area of any floor, then the Premises also exclude the common corridors, elevator lobby and toilets located on such floor. 

1.04    “Base Rent”: 
  

													
	 Months of Term
	  	Annual Rate
Per Square Foot	 	  	Annual
Base Rent	 	  	Monthly
Base Rent	 
	 Months 1-4
	  	$	0	 	  	$	0	 	  	$	0	 
	 Months 5-12*
	  	$	31.50	* 	  	$	315,000.00	* 	  	$	26,250.00	* 
	 Months 13-24
	  	$	32.50	 	  	$	424,645.00	 	  	$	35,387.08	 
	 Months 25-36
	  	$	33.50	 	  	$	437,711.00	 	  	$	36,475.92	 
	 Months 37-48
	  	$	34.50	 	  	$	450,777.00	 	  	$	37,564.75	 
	 Months 49-63
	  	$	35.50	 	  	$	463,843.00	 	  	$	38,653.58	 

  

	*	Notwithstanding the Rentable Square Footage of the Premises, Base Rent during the period from Month 5 through Month 12 shall be calculated as if the Rentable Square Footage of the Premises were only 10,000 rentable
square feet; provided however, that if Tenant shall Default under this Lease prior to the end of Month 12, then Base Rent for the remainder of this period shall be calculated based on the actual Rentable Square Footage of the Premises.

 1.05    “Tenant’s Pro Rata Share”: 12.6628% 

“Base Year” for Taxes (defined in Exhibit B): Fiscal Year (defined below) 2017 (i.e., July 1, 2016 to
June 30, 2017); “Base Year” for Expenses (defined in Exhibit B): calendar year 2017. 
 For purposes
hereof, “Fiscal Year” shall mean the Base Year for Taxes and each period of July 1 to June 30 thereafter. 

1.06    “Term”: The period commencing on the Commencement Date (defined below) and, unless terminated
earlier in accordance with this Lease, ending on the last day of the 63rd full calendar month following the Commencement Date (the “Termination Date”). 

1.07    “Commencement Date”: The date upon which Landlord delivers possession of the Premises to Tenant
with the Landlord Work (as defined below) substantially complete; provided, however, that if Landlord shall be delayed in substantially completing the Landlord Work in the Premises as a result of the occurrence of a Tenant Delay (as defined below),
then, for purposes of determining the Commencement Date, the date of substantial completion shall be deemed to be the day that the Landlord Work would have been substantially completed absent any such Tenant Delay. 

1.08    “Target Commencement Date”: August 24, 2017 

1.09    “Rent Commencement Date”: The date that is four (4) calendar months following the
Commencement Date; provided that if Tenant shall Default under this Lease prior to the Rent Commencement Date, the Rent Commencement Date shall be deemed to be the Commencement Date. 

1.10    “Security Deposit”: $182,379.60 in the form of a Letter of Credit as set forth in
Section 6 hereof. 
 1.11    “Brokers”: T3 Advisors, who represented Tenant in connection
with this transaction, and Cushman and Wakefield, who represented Landlord in connection with this transaction. 

1.12    “Permitted Use”: General office use and for no other purpose. 

1.13    “Notice Address(es)”: 
  

			
	 Landlord:
  

NEEP Investors Holdings LLC
 c/o National Development

2310 Washington Street
 Newton Lower Falls, MA 02462

Attention: President
  

With copies of any notices to Landlord
 sent to:
	  	 Tenant:
  

Prior to the Commencement Date:
  

ScPharmaceuticals Inc.
 131 Hartwell Avenue, Suite 215

Lexington, MA 02421
 Attn: Chief Financial Officer

 
 From and after the

Commencement Date:

  
 2 

			
	 National Development
 2310 Washington Street

Newton Lower Falls, MA 02462
 Attn: Richard P. Schwartz,
Esq.
	  	 ScPharmaceuticals Inc.
 2400 District Avenue

Suite 310
 Burlington, MA 01803

Attn: Chief Financial Officer

 1.14    “Business Day(s)” are Monday through Friday of each week,
exclusive of New Year’s Day, Presidents Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day and Christmas Day (“Holidays”). “Building Service Hours” are 8:00 A.M. to
6:00 P.M. on Business Days and 9:00 A.M. to 1:00 P.M. on Saturdays. 

1.15    “Landlord Work” as defined in Section 3.02 hereof. 

1.16    “Property” means the Building and the parcel(s) of land on which it is located and, at
Landlord’s discretion, the parking facilities and other improvements, if any, serving the Building and the parcel(s) of land on which they are located. The Property is more particularly described on Exhibit
A-2, attached. 
 1.17    “Letter of Credit” as described
in Section 6 hereof. 
  

	2.	Lease Grant. 

 Landlord hereby leases the Premises to Tenant and Tenant hereby leases the Premises from
Landlord. Tenant has the non-exclusive right to use any portions of the Property that are designated by Landlord from time to time for the common use of tenants and others, including without limitation
exterior walls, the common stairways and stairwells, and common toilets, entranceways and lobbies, elevators and elevator wells, fan rooms, electric and telephone closets (other than those exclusively serving the Premises, if any), janitor closets,
freight elevators and loading areas, and pipes, ducts, conduits, wires and appurtenant fixtures serving other parts of the Property (exclusively or in common) and other common areas and facilities from time to time designated as such by Landlord
(the “Common Areas”), including, without limitation, parking as set forth in Exhibit F attached hereto. 
  

	3.	Condition of Premises; Landlord Work. 

 3.01    Condition of
Premises. Tenant has inspected the Premises and agrees to accept the same in their “as is” condition and configuration without any representations or warranties by Landlord and with no obligation on the part of Landlord to perform any
alterations, improvements or additions in, or to, the Premises, other than the Landlord Work (as defined below). By taking possession of the Premises, Tenant agrees that the Premises are in good order and satisfactory condition, subject only to the
completion, if applicable, of punch list items as set forth below and Landlord’s correction of any latent defects within one (1) year of substantial completion of the Landlord Work as set forth in Section 3.02. Subject
to the terms of Section 3.03 below, Tenant shall not be permitted to take possession of or enter the Premises prior to the Commencement Date without Landlord’s permission. 

3.02    Landlord Work. Landlord shall perform the work shown and described on the Premises fit plan attached hereto
as Exhibit C-1 (the “Plan”) to prepare the Premises for occupancy by Tenant, in a good and workmanlike manner, and in accordance with the Building Standard Specifications attached
hereto as Exhibit C-2 and applicable Laws (as defined below) (the “Building Standard Specifications”) and subject to the terms of the Work Letter attached

  
 3 

 
hereto as Exhibit C (the “Landlord Work”), and, subject to Force Majeure (as hereinafter defined), and Tenant Delay shall use commercially reasonable efforts to
cause the Commencement Date to occur on about the Target Commencement Date, but without penalty, cost or liability to Landlord in connection with any failure to do so; provide however, that in the event that the Commencement Date has not occurred,
for any reason other than a Tenant Delay or Force Majeure delay, on or before (a) the date that is thirty (30) days after the Target Commencement Date, then Tenant shall be entitled to an abatement of Base Rent equal to one
(1) day for each day until the Commencement Date occurs beginning on such thirtieth (30th) day and continuing until the date that is sixty (60) days after the Target Commencement
Date, and, if applicable, (b) the date that is sixty (60) days after the Target Commencement Date, then Tenant shall be entitled to an abatement of Base Rent equal to two (2) days for each day beginning on such sixtieth (60th) day and continuing until the Commencement Date occurs. The Landlord Work shall be deemed to be substantially completed (and substantial completion shall be deemed to have occurred) on the later to
occur of (i) the date that Landlord reasonably determines that all Landlord Work in such space has been performed (or would have been performed absent any Tenant Delays), other than any details of construction, mechanical adjustment or
any other matter, the non-completion of which does not materially interfere with Tenant’s use of the Premises; and (ii) the date Landlord receives from the appropriate governmental authorities, with
respect to the Landlord Work performed by Landlord or its contractors in the Premises, all approvals necessary for Tenant’s initial occupancy of the Premises. Tenant’s acceptance of possession of the Premises shall be subject to
Landlord’s obligation to complete any aspects of the Landlord Work as may be set forth on a construction punch list prepared by Landlord and Tenant in accordance with the terms hereof. Prior to substantial completion of the Landlord Work in the
Premises, but in no event later than five (5) days following notice from Landlord to Tenant requesting to schedule such inspection, Landlord and Tenant shall together conduct an inspection of the space and prepare a “punch
list” setting forth any portions of the Landlord Work that are not in conformity with the Landlord Work as required by the terms of this Lease. Notwithstanding the foregoing, at the request of Landlord, such construction punch list shall be
mutually prepared by Landlord and Tenant prior to the date on which Tenant first begins to move its furniture, equipment or other personal property into any portion of the Premises (or such later date acceptable to Landlord), if in Landlord’s
reasonable determination such activity by Tenant could result in damage to the Premises or the Landlord Work. Landlord, as part of the Landlord Work, shall use diligent and good faith efforts to complete all such items as soon as is reasonably
practicable following the preparation of the punch list, and Tenant shall provide access to the Premises for the completion of such work, but in no event more than sixty (60) days following the Commencement Date. 

3.03    Early Access to Premises. If Tenant is permitted by Landlord to take possession of the Premises before the
Commencement Date, such possession shall be subject to the terms and conditions of the Lease, and Tenant shall pay Base Rent and Additional Rent applicable to the Premises to Landlord for each day of possession prior to the Commencement Date for
same. Notwithstanding the foregoing, provided such access does not materially interfere with the performance of the Landlord Work, Tenant shall have access to, and shall not be required to pay Rent for (except for the cost of any building services
requested by Tenant during any such period), the Premises during the period that is thirty (30) days prior to the Commencement Date for the sole purpose of installing telephone and data cabling, furniture, fixtures, equipment or other
personal property. 

  
 4 

 3.04    Commencement Letter. Promptly following the date on which the
Commencement Date has been determined, Landlord and Tenant shall execute and deliver a commencement letter in substantially the form attached hereto as Exhibit D (the “Commencement Letter”), which Commencement Letter shall
memorialize the Commencement Date, Rent Commencement Date, Transaction Costs and Termination Date; provided, however, the failure of either party to execute the Commencement Letter shall not affect the rights of either party hereunder. 

 

	4.	Rent. 

 4.01    From and after the Commencement Date, Tenant shall
pay Landlord, without any setoff or deduction, unless expressly set forth in this Lease, all Base Rent and Additional Rent due for the Term (collectively referred to as “Rent”). “Additional Rent” means all
sums (exclusive of Base Rent) that Tenant is required to pay Landlord under this Lease. Tenant shall pay and be liable for all rental, sales and use taxes (but excluding income taxes), if any, imposed upon or measured by Rent. Base Rent and
recurring monthly charges of Additional Rent shall be due and payable in advance on the first day of each calendar month without notice or demand. All other items of Rent shall be due and payable by Tenant on or before thirty (30) days
after billing by Landlord. Rent shall be made payable to the entity, and sent to the address, Landlord designates and shall be made by good and sufficient check payable in United States of America currency or by other means designated by Landlord
from time to time. If Tenant does not pay any Rent when due hereunder, Tenant shall pay Landlord an administration fee in the amount of $500.00, provided that Tenant shall be entitled to a grace period of up to five (5) days for the
first late payment of Rent in a calendar year; provided, however, Landlord shall waive the administration fee for one (1) late payment in any twelve (12) month period during the Term. In addition, past due Rent shall accrue
interest at twelve percent (12%) per annum, and Tenant shall pay Landlord a reasonable fee for any checks returned by Tenant’s bank for any reason. Nothing in this paragraph shall be deemed to waive or condition any claim of Default by Landlord
for Tenant’s failure to timely pay Rent, which is governed by Section 18, below. Landlord’s acceptance of less than the correct amount of Rent shall be considered a payment on account of the oldest obligation due from Tenant
hereunder, then to any current Rent then due hereunder, notwithstanding any statement to the contrary contained on or accompanying any such payment from Tenant. Rent for any partial month during the Term shall be prorated. No endorsement or
statement on a check or letter accompanying payment shall be considered an accord and satisfaction. Tenant’s obligation so to pay Rent under the Lease shall be absolute, unconditional, and independent and shall not be discharged or otherwise
affected by any law or regulation now or hereafter applicable to the Premises, or any other restriction on Tenant’s use, or, except as expressly provided in the Lease, any casualty or taking, or any failure by Landlord to perform or other
occurrence; and Tenant waives all rights now or hereafter existing to assert any defense in the nature of constructive eviction to any action seeking to recover Rent. 

4.02    Tenant shall pay Tenant’s Pro Rata Share of Expense Excess and Tax Excess in accordance with Exhibit B
of this Lease. 
  

	5.	Compliance with Laws; Use. 

 The Premises shall be used for the Permitted Use and for no other use
whatsoever. Tenant shall comply with all statutes, codes, ordinances, orders, rules and regulations of any municipal or governmental entity whether in effect now or later, including the Americans with Disabilities Act and the rules and regulations
of the Massachusetts Architectural Access Board (“Law(s)”), regarding the operation of Tenant’s business, the use, condition, configuration and occupancy of the Premises and the Building systems located in or
exclusively serving the Premises. 

  
 5 

 
Notwithstanding anything to the contrary contained herein, Tenant shall, at its sole cost and expense, promptly comply with any Laws that relate to the Premises or the “Base
Building” (defined below), but only to the extent such obligations are triggered by Tenant’s specific use of the Premises, other than for general office use, or Alterations or improvements in the Premises performed or requested by
Tenant (other than Landlord Work). “Base Building” shall include the structural portions of the Building, the public restrooms and the Building mechanical, electrical and plumbing systems and equipment located in the internal
core of the Building on the floor or floors on which the Premises are located. Tenant shall promptly provide Landlord with copies of any notices it receives regarding an alleged violation of Law. Effective as of the Effective Date, Landlord agrees
that, to the best of its knowledge, the Base Building (as defined below) and the Base Building systems are in good working order and condition, are in compliance with all Laws, and are fit for their intended purposes. Tenant shall not exceed the
standard density limit for the Building. Tenant shall comply with the rules and regulations of the Building attached as Exhibit E and such other reasonable rules and regulations adopted by Landlord from time to time, including rules and
regulations for the performance of Alterations (defined in Section 9.03). All such changes to rules and regulations will be sent by Landlord to Tenant in writing. In the event of a conflict between the rules and regulations and the terms of
this Lease, the terms of this Lease shall control. Landlord shall not knowingly enforce the rules and regulations against Tenant in a discriminatory manner. 
  

	6.	Security Deposit. 

 The Security Deposit shall be delivered to Landlord upon the execution of this Lease
by Tenant and held by Landlord without liability for interest (unless required by Law) as security for the performance of Tenant’s obligations. The Security Deposit is not an advance payment of Rent or a measure of damages. If Tenant is in
Default, Landlord may from time to time and without prejudice to any other remedy provided in this Lease or by Law, use all or a portion of the Security Deposit to the extent necessary to satisfy past due Rent or to satisfy any other loss or damage
resulting from Tenant’s Default under this Lease. If Landlord uses any portion of the Security Deposit, Tenant, within 10 days after written demand, shall restore the Security Deposit to its original amount. Landlord shall return any unapplied
portion of the Security Deposit to Tenant within forty-five (45) days following the Termination Date or earlier expiration of this Lease. Landlord may assign the Security Deposit to a successor or transferee and, following the assignment,
Landlord shall have no further liability for the return of the Security Deposit. Landlord shall not be required to keep the Security Deposit separate from its other accounts. 

Notwithstanding anything in this Section 6 to the contrary, Tenant shall satisfy the requirement of delivery of the Security Deposit by the delivery to
Landlord of an unconditional and irrevocable letter of credit (“Letter of Credit”) in the amount of the Security Deposit set forth in Section 1.10 above, and in a form acceptable to Landlord in its reasonable discretion.
The Letter of Credit shall be issued by a bank reasonably satisfactory to Landlord; provided that Landlord hereby approves Silicon Valley Bank as the issuing bank. Tenant shall ensure that at all times after the execution and delivery of this Lease
until forty-five (45) days after the Termination Date, as the same may be extended, an unexpired Letter of Credit in the amount of the Security Deposit set forth in Section 1.10 above shall be in the possession of Landlord. The Letter of
Credit shall contain a so-called “evergreen” clause providing that the Letter of Credit shall not be canceled unless the issuing bank delivers thirty (30) days’ prior written notice to
Landlord. Tenant shall deliver to Landlord, no later than ten (10) days prior to the expiry date of the then outstanding and expiring Letter of Credit (a) a replacement Letter of Credit or (b) cash in the amount then required as the
Security Deposit. Landlord shall be entitled to draw on the Letter of Credit (i) if Tenant fails to deliver any replacement Letter of Credit or pay the amount of 

  
 6 

 
the Security Deposit in cash as required, in which event Landlord shall be permitted to retain the entire proceeds of such Letter of Credit for application as the Security Deposit hereunder,
(ii) to cure or attempt to cure, in whole or in part, any Default by Tenant under this Lease, in which event Tenant shall replenish the amount so drawn upon demand by Landlord, and (iii) if the credit rating of the long-term debt of the
issuer of the Letter of Credit (according to Moody’s or similar national rating agency) is downgraded to a grade below investment rate), or if the issuer of the Letter of Credit shall enter into any supervisory agreement with any governmental
authority, or if the issuer of the Letter of Credit shall fail to meet any capital requirements imposed by applicable Law, unless Tenant delivers to Landlord a replacement Letter of Credit complying with the terms of this Lease or cash in the amount
required as the Security Deposit within ten (10) days after written demand therefor from Landlord. Each Letter of Credit shall be for the benefit of Landlord and its successors and assigns and shall entitle Landlord or its successors or assigns
to draw from time to time under the Letter of Credit in portions or in whole upon presentation of a sight draft and statement by Landlord that Landlord is entitled to draw thereunder pursuant to the terms and provisions of this Lease. Landlord shall
have an unrestricted right to transfer the Letter of Credit at any time and to any party selected by the Landlord. Tenant shall pay any transfer commission (fee) and all other costs (hereinafter collectively referred to as the “Transfer
Fee”) which may be imposed by the bank issuing the Letter of Credit for the transfer of the Letter of Credit by Landlord. The Tenant’s failure to pay the Transfer Fee, which failure continues for ten (10) days following
written notice from Landlord of same, shall constitute a Default of this Lease, and Landlord shall have the right to pursue any and all remedies provided Landlord under this Lease, in equity and at law. 

 

	7.	Building Services. 

 7.01    Landlord shall furnish Tenant with the
following services: (a) hot and cold water for use in the Base Building lavatories and drinking purposes; (b) customary heat and air conditioning in season during Building Service Hours (, although (i) Tenant
shall have the right to receive HVAC service during hours other than Building Service Hours by paying Landlord’s then standard charge for additional HVAC service and providing such prior notice as is reasonably specified by Landlord
(Landlord’s current charge for afterhours HVAC is $60 per hour, subject to change by Landlord from time to time), and (ii) if Tenant is permitted to connect any supplemental HVAC units to the Building’s condenser water loop or
chilled water line, such permission shall be conditioned upon Landlord having adequate excess capacity from time to time and such connection and use shall be subject to Landlord’s reasonable approval and reasonable restrictions imposed by
Landlord, and Landlord shall have the right to charge Tenant a connection fee and/or a monthly usage fee, as reasonably determined by Landlord; (c) standard janitorial service on Business Days; (d) unattended elevator
service; (e) electricity in accordance with the terms and conditions in Section 7.02; (f) access to the Building for Tenant and its employees 24 hours per day/7 days per week, subject to the terms of this Lease and such
protective services or monitoring systems, if any, as Landlord may reasonably impose, including, without limitation, sign-in procedures and/or presentation of identification cards; and (g) subject
to Section 26.10, such other services as Landlord reasonably determines are necessary or appropriate for the Property. If Landlord, at Tenant’s request, provides any services which are not Landlord’s express obligation under
this Lease, including, without limitation, any repairs which are Tenant’s responsibility pursuant to Section 9 below, Tenant shall pay Landlord, or such other party designated by Landlord, the cost of providing such service plus an
administrative charge of ten percent (10%), the same to constitute Additional Rent hereunder. 

  
 7 

 7.02    Electricity used by Tenant in the Premises shall, at Landlord’s
option, be paid for by Tenant by a separate, flat-rate charge (except the same may be increased as hereinafter provided in this Section 7.02) payable by Tenant to Landlord monthly with Rent, initially estimated (at the rate of $1.50 per
rentable square foot of the Premises) to be in the amount of $1,633.25 per month ($19,599.00 per annum), payable as Additional Rent hereunder. Landlord shall have the right from time to time to reasonably increase such monthly flat-rate amount
payable by Tenant hereunder based on actual increases in the cost of electricity (and/or the generation thereof) to Landlord in connection with the Property with no mark up by Landlord. Without the consent of Landlord, Tenant’s use of
electrical service shall not exceed the Building standard usage of six (6) watts per square foot, as reasonably determined by Landlord, based upon the Building standard electrical design load. Landlord shall have the right to measure
electrical usage by commonly accepted methods, including the installation of measuring devices such as submeters and check meters. If it is determined that Tenant is using electricity in such quantities or during such periods as to cause the total
cost of Tenant’s electrical usage, on a monthly, per-rentable-square-foot basis, to materially exceed that which Landlord reasonably deems to be standard for the Building, Tenant shall pay Landlord
Additional Rent for the cost of such excess electrical usage and, if applicable, for the cost of purchasing and installing the measuring device(s). 

7.03    Landlord’s failure to furnish, or any interruption, diminishment or termination of services due to the
application of Laws, the failure of any equipment, the performance of maintenance, repairs, improvements or alterations, utility interruptions or the occurrence of an event of Force Majeure (defined in Section 26.03) (collectively a
“Service Failure”) shall not render Landlord liable to Tenant, constitute a constructive eviction of Tenant, give rise to an abatement of Rent, nor relieve Tenant from the obligation to fulfill any covenant or agreement.
Notwithstanding the foregoing, if all or any portion of the Premises is rendered Untenantable (as defined below) solely as a result of the failure of any Essential Service (as defined below) due to Landlord’s negligence or willful misconduct
and Tenant does not use or occupy the same during said period, then Tenant’s obligation pay Base Rent and Additional Rent hereunder shall be abated in proportion to the portion of the Premises rendered Untenantable until the date on which such
Untenantability is cured, provided that such abatement shall not commence until the fifth (5th) Business Day after the date on which Tenant delivers written notice to Landlord of the interruption and an opportunity, within such five
(5) Business Day period, to cure same. The rate at which Base Rent or Additional Rent may be abated under this Section 7.03 in any one calendar month shall not exceed twenty-five percent (25%) of the Base Rent payable for
such calendar month, provided that any amount not permitted to be taken as an abatement as a result of such monthly cap shall be credited against the Base Rent or Additional Rent next thereafter due under this Lease, subject to such monthly cap. In
the event that the foregoing monthly cap would have the effect of depriving Tenant of any portion of abatement to which it is otherwise entitled hereunder due to the number of calendar months remaining in the term, the monthly cap may be increased
proportionately to the extent necessary to avoid such result. 
 As used herein, the terms “Untenantable” and
“Untenantability” shall mean that Tenant shall not be reasonably able to use and occupy, or to have access to, the Premises or such applicable portion thereof for the normal conduct of Tenant’s business operations
without extraordinary and unreasonable measures being required to be taken by Tenant in order to do so. As used herein, the term “Essential Services” shall mean, in each case to the extent of Landlord’s obligation to
provide such service under this Lease, (i) access to the Premises, (ii) HVAC, (iii) use of one (1) or more elevators in the Building, (iv) electricity, (v) parking, (vi) water and (vii) sewer/septic service. 

  
 8 

	8.	Leasehold Improvements. 

 All improvements in and to the Premises, including any Alterations (defined in
Section 9.03) (collectively, “Leasehold Improvements”) shall remain upon the Premises at the end of the Term without compensation to Tenant, provided that Tenant, at its expense, shall remove any Cable (defined in
Section 9.01 below). In addition, Landlord, by written notice to Tenant at least thirty (30) days prior to the Termination Date, may require Tenant, at Tenant’s expense, to remove any Alterations that, in Landlord’s reasonable
judgment, are of a nature that would require removal and repair costs that are materially in excess of the removal and repair costs associated with standard office improvements (the Cable and such other items collectively are referred to as
“Required Removables”). Required Removables shall include, without limitation, internal stairways, raised floors, personal baths and showers, vaults, rolling file systems and structural alterations and modifications; provided,
however, in no event shall Tenant be required to remove any of the Landlord Work. The Required Removables shall be removed by Tenant on or prior to the Termination Date. Tenant shall repair damage caused by the installation or removal of Required
Removables. If Tenant fails to perform its obligations in a timely manner, Landlord may perform such work at Tenant’s expense. Tenant, at the time it requests approval for a proposed Alteration, may request in writing that Landlord advise
Tenant whether the Alteration, or any portion thereof, is a Required Removable. Within ten (10) days after receipt of Tenant’s request, Landlord shall advise Tenant in writing as to which portions of the alteration or other improvements
are Required Removables. 
  

	9.	Repairs and Alterations. 

 9.01    Tenant shall promptly provide
Landlord with notice of any conditions within the Premises that are dangerous or in need of maintenance or repair. Tenant, at its sole cost and expense, shall perform all maintenance and repairs to the Premises that are not Landlord’s express
responsibility under this Lease, and keep the Premises in good condition and repair, reasonable wear and tear and casualty and condemnation excepted. Tenant’s repair and maintenance obligations include, without limitation, repairs to:
(a) floor covering; (b) interior partitions; (c) doors; (d) the interior side of demising walls; (e) Alterations (described in Section 9.03); (f) supplemental air conditioning units, kitchens,
including hot water heaters, plumbing, and similar facilities exclusively serving Tenant, whether such items are installed by Tenant or are currently existing in the Premises; and (g) electronic, fiber, phone and data cabling and related
equipment that is installed by or for the exclusive benefit of Tenant (collectively, “Cable”). All repairs and other work performed by Tenant or its contractors, including that involving Cable, shall be subject to the terms of
Section 9.03 below. If Tenant fails to make any repairs to the Premises for more than fifteen (15) days after written notice from Landlord (although notice shall not be required in an emergency) within applicable cure periods
pursuant to Article 18 hereof, Landlord may make the repairs, and, within thirty (30) days after demand, Tenant shall pay the reasonable cost of the repairs, together with an administrative charge in an amount equal to ten percent (10%)
of the cost of the repairs. 
 9.02    Landlord shall keep and maintain in good repair and working order and perform
maintenance upon the: (a) structural elements of the Building; (b) mechanical (including HVAC), electrical, plumbing and fire/life safety systems serving the Building in general; (c) Common Areas;
(d) roof of the Building; (e) exterior windows of the Building; and (f) elevators serving the Building. Landlord shall promptly make repairs for which Landlord is responsible. 

  
 9 

 9.03    Tenant shall not make alterations, repairs, additions or improvements
or install any Cable (collectively referred to as “Alterations”) without first obtaining the written consent of Landlord in each instance, such consent not to be unreasonably withheld, conditioned or delayed. However,
Landlord’s consent shall not be required for any Alteration that satisfies all of the following criteria (a “Cosmetic Alteration”): (a) is of a cosmetic nature such as painting, wallpapering, hanging pictures and
installing carpeting; (b) is not visible from the exterior of the Premises or Building; (c) will not affect the Base Building (defined in Section 5); and (d) does not require work to be performed
inside the walls or above the ceiling of the Premises. Cosmetic Alterations shall be subject to all the other provisions of this Section 9.03. Prior to starting work, Tenant shall furnish Landlord with plans and specifications (which shall be
in CAD format if requested by Landlord); names of contractors reasonably acceptable to Landlord (provided that Landlord may designate specific contractors with respect to Base Building and vertical Cable, as may be described more fully below);
required permits and approvals; evidence of contractor’s and subcontractor’s insurance in amounts reasonably required by Landlord and naming Landlord and the managing agent for the Building (or any successor(s)) as additional insureds; and
any security for performance in amounts reasonably required by Landlord. Landlord may designate specific contractors with respect to oversight, installation, repair, connection to, and removal of vertical Cable. All Cable shall be clearly marked
with adhesive plastic labels (or plastic tags attached to such Cable with wire) to show Tenant’s name, suite number, and the purpose of such Cable (i) every six (6) feet outside the Premises (specifically including, but
not limited to, the electrical room risers and any Common Areas), and (ii) at the termination point(s) of such Cable. Changes to the plans and specifications must also be submitted to Landlord for its approval. Alterations shall be
constructed in a good and workmanlike manner using materials of a quality reasonably approved by Landlord, and Tenant shall ensure that no Alteration impairs any Building system or Landlord’s ability to perform its obligations hereunder. Tenant
shall reimburse Landlord for any sums paid by Landlord for third party examination of Tenant’s plans for non-Cosmetic Alterations. Upon completion, Tenant shall furnish “as-built” plans (in CAD
format, if requested by Landlord) for non-Cosmetic Alterations, completion affidavits and full and final waivers of lien. In addition, Tenant shall pay Landlord a fee for Landlord’s oversight and
coordination of any non-Cosmetic Alterations equal to ten percent (10%) of the cost of the non-Cosmetic Alterations. Landlord’s approval of an Alteration shall not
be deemed a representation by Landlord that the Alteration complies with Law. 
 Landlord agrees not to withhold or delay its consent unreasonably to any
Alterations that (i) do not affect base Building systems or the structure of the Building, (ii) are not visible from the outside the Premises, and (iii) would not materially detract from the aesthetic integrity of the Building or its
design. Landlord shall not be deemed to have acted unreasonably if it withholds its consent because, in Landlord’s opinion, such work: could affect the safety of the Building or its occupants; would increase Landlord’s cost of repairs,
insurance or furnishing services or otherwise adversely affect Landlord’s ability to efficiently operate the Building or furnish services to Tenant or other tenants; involves toxic or hazardous materials; could be costly or hazardous to remove
or demolish; requires entry into another tenant’s premises or use of public areas; or is prohibited by any mortgage on the Building. The foregoing reasons, however, shall not be exclusive of the reasons for which Landlord may withhold consent,
whether or not such other reasons are similar or dissimilar to the foregoing. 
 Subject to the foregoing provisions of this Section 9, including,
without limitation, Landlord’s prior written approval of all plans and specifications and Tenant’s contractor, Tenant may, at Tenant’s sole cost and expense, install in the Premises a security card access system compatible with the
Building’s security card access system. Tenant shall provide Landlord with access cards or codes necessary for access to the Premises by Landlord in connection with the performance of its obligations and/or the exercise of its rights under this
Lease. 

  
 10 

	10.	Entry by Landlord. 

 Landlord may enter the Premises to inspect, show or clean the Premises or to perform
or facilitate the performance of repairs, alterations or additions to the Premises or any portion of the Building. Except in emergencies or to provide Building services, Landlord shall provide Tenant with reasonable prior written notice (which in
such cases may be by email) of entry and shall use reasonable efforts to minimize any interference with Tenant’s use of the Premises. If reasonably necessary, Landlord may temporarily close all or a portion of the Premises to perform repairs,
alterations and additions. However, except in emergencies, Landlord will not close the Premises if the work can reasonably be completed on weekends and after Building Service Hours. Entry by Landlord in accordance with this Section shall not
constitute a constructive eviction or entitle Tenant to an abatement or reduction of Rent. 
  

	11.	Assignment and Subletting. 

 11.01    Except in connection with a
Business Transfer (defined in Section 11.04), Tenant shall not assign, sublease, transfer or encumber any interest in this Lease or allow any third party to use any portion of the Premises (collectively or individually, a
“Transfer”) without the prior written consent of Landlord. Landlord shall not unreasonably withhold, condition or delay its consent to any assignment of this Lease if Landlord does not exercise its recapture rights under
Section 11.02. Without limitation, it is agreed that Landlord’s consent to any assignment or sublet shall not be considered unreasonably withheld if the proposed transferee is a governmental entity or an occupant of the Building or
an occupant of any other buildings within the same project or if the proposed transferee, whether or not an occupant of the Building or an occupant of any other buildings within the same project, is, or has been within the last six
(6) months, in discussions with Landlord or any affiliate of Landlord regarding the leasing of space within the Building or within any other buildings within the Park, but only to the extent Landlord has similar space currently available
for lease. Without limiting the foregoing, a Transfer shall be deemed to include any change in control in at least fifty percent (50%) of the voting rights/shares of Tenant (other than through a change in the ownership of voting securities listed on
a recognized public securities exchange). Any Transfer in violation of this Section shall, at Landlord’s option, be deemed a Default by Tenant as described in Section 18, and shall be voidable by Landlord. In no event shall any
Transfer, including a Business Transfer, release or relieve Tenant from any obligation under this Lease, and Tenant shall remain primarily liable for the performance of the tenant’s obligations under this Lease, as amended from time to time.
Without otherwise limiting the criteria upon which Landlord may withhold its consent, Landlord shall be entitled to consider all reasonable criteria including, but not limited to, the following: (1) whether or not the proposed transferee
is engaged in a business which, and the use of the Premises for the Permitted Use, (2) whether the use to be made of the Premises by the proposed transferee will conflict with any so-called “exclusive” use then in favor of any
other tenant of the Building or the Park (Landlord hereby confirming that, as of the Effective Date, there are no such exclusives that affect the Permitted Use), and whether such use would be prohibited by any other portion of this Lease, including,
but not limited to, any rules and regulations then in effect, or under applicable Laws, and whether such use imposes a greater load upon the Premises and the Building and the Park services than imposed by Tenant, (3), and (3) the
creditworthiness and financial stability of the proposed transferee in light of the responsibilities involved. 

  
 11 

 11.02    Tenant shall provide Landlord with financial statements for the
proposed transferee (or, in the case of a change of ownership or control, for the proposed new controlling entity(ies)), a fully executed copy of the proposed assignment or sublease (or, where applicable, other Transfer) documentation and such other
information as Landlord may reasonably request. Within fifteen (15) days after receipt of the required information and documentation, Landlord shall either: (a) consent to any assignment or sublet by execution of a consent agreement
in a form reasonably designated by Landlord; (b) reasonably refuse to consent to any assignment or sublet in writing; or (c) in the event of an assignment of this Lease or subletting of more than fifty percent (50%) of the
Rentable Square Footage of the Premises for the then remaining Term (excluding unexercised options), recapture the portion of the Premises that Tenant is proposing to assign or sublet. If Landlord exercises its right to recapture, this Lease shall
automatically be amended (or terminated if the entire Premises is being assigned or sublet) to delete the applicable portion of the Premises effective on the proposed effective date of the Transfer, although Landlord may require Tenant to execute a
reasonable amendment or other document reflecting such reduction or termination. Tenant shall pay Landlord a review fee of up to $1,500.00 for Landlord’s out of pocket costs in connection with Landlord’s review of any requested Transfer,
whether or not Landlord approves same. 
 11.03    Tenant shall pay Landlord fifty percent (50%) of all rent and other
consideration which Tenant receives as a result of a Transfer that is in excess of the Rent payable to Landlord for the portion of the Premises and Term covered by the Transfer. Tenant shall pay Landlord for Landlord’s share of the excess
within thirty (30) days after Tenant’s receipt of the excess. In determining the excess due Landlord, Tenant may deduct from the excess, on a straight-line basis, all reasonable and customary expenses directly incurred by Tenant
attributable to the Transfer. If Tenant is in Default, Landlord may require that all sublease payments be made directly to Landlord, in which case Tenant shall receive a credit against Rent in the amount of Tenant’s share of payments received
by Landlord. In no event shall Tenant be permitted to enter into any sublease or assignment that would result in the characterization of any amounts received by Landlord pursuant to this Section 11.03 as amounts that are not rents from
real property as provided under Section 26.13, below. 
 11.04    Subject to Section 26.13, Tenant may
assign this Lease to a successor to Tenant by merger, consolidation, corporate reorganization or the purchase of substantially all of Tenant’s assets, or assign this Lease or sublet all or a portion of the Premises to an Affiliate (defined
below), without the consent of Landlord, provided that all of the following conditions are satisfied (a “Business Transfer”): (a) Tenant must not be in Default; (b) Tenant must give Landlord written notice at
least fifteen (15) days before such Transfer; and (c) except in the case of an assignment or sublease to an Affiliate, the Credit Requirement (defined below) must be satisfied. Tenant’s notice to Landlord shall include
information and documentation evidencing the Business Transfer and showing that each of the above conditions has been satisfied. If requested by Landlord, Tenant’s successor shall sign and deliver to Landlord a commercially reasonable form of
assumption agreement. “Affiliate” shall mean an entity controlled by, controlling or under common control with Tenant. The “Credit Requirement” shall be deemed satisfied if, following the date of the
Business Transfer, the financial strength of the resulting Tenant is not less than that of Tenant on the date that the series of events culminating in the applicable Transfer occurred or at the execution of this Lease, whichever is greater, as
reasonably determined by Landlord (x) based on credit ratings of such entity and Tenant by both Moody’s and Standard & Poor’s (or by either such agency alone, if applicable ratings by the other agency do not
exist), or (y) if such credit ratings do not exist, then in accordance with Moody’s KMV RiskCalc (i.e., the on-line software tool offered by Moody’s for analyzing credit risk) based on CFO-certified financial statements for
such entity and Tenant covering their last two fiscal years ending before the Transfer. 

  
 12 

 11.05    Notwithstanding anything to the contrary contained in this
Section 11, neither Tenant nor any other person having a right to possess, use, or occupy (for convenience, collectively referred to in this subsection as “Use”) the Premises shall enter into any lease, sublease,
license, concession or other agreement for Use of all or any portion of the Premises which provides for rental or other payment for such Use based, in whole or in part, on the net income or profits derived by any person that leases, possesses, uses,
or occupies all or any portion of the Premises (other than an amount based on a fixed percentage or percentages of receipts or sales), and any such purported lease, sublease, license, concession or other agreement shall be absolutely void and
ineffective as a transfer of any right or interest in the Use of all or any part of the Premises. 
  

	12.    Liens.	

 Tenant shall not permit mechanics’ or other liens to be placed upon the Property, Premises or
Tenant’s leasehold interest in connection with any work or service done or purportedly done by or for the benefit of Tenant or its subtenants or transferees. Tenant shall give Landlord notice at least fifteen (15) days prior to the
commencement of any work in the Premises to afford Landlord the opportunity, where applicable, to post and record notices of non-responsibility. Tenant, within fifteen (15) days of written notice of any
such liens, shall fully discharge any lien by settlement, by bonding or by insuring over the lien in the manner prescribed by the applicable lien Law and, if Tenant fails to do so, Tenant shall be deemed in Default under this Lease and, in addition
to any other remedies available to Landlord as a result of such Default by Tenant, Landlord, at its option, may bond, insure over or otherwise discharge the lien. Tenant shall reimburse Landlord for any amount paid by Landlord, including, without
limitation, reasonable attorneys’ fees. Landlord shall have the right to require Tenant to post a performance or payment bond in connection with any work or service done or purportedly done by or for the benefit of Tenant. Tenant acknowledges
and agrees that all such work or service is being performed for the sole benefit of Tenant and not for the benefit of Landlord. 
  

	13.	Indemnity and Waiver of Claims. 

 13.01    Except to the extent
caused by the negligence or willful misconduct of Landlord or any Landlord Related Parties (defined below), Tenant shall indemnify, defend and hold Landlord and Landlord Related Parties harmless against and from all liabilities, obligations,
damages, penalties, claims, actions, costs, charges and expenses, including, without limitation, reasonable attorneys’ fees and other professional fees (if and to the extent permitted by Law) (collectively referred to as
“Losses”), which may be imposed upon, incurred by or asserted against Landlord or any of the Landlord Related Parties by any third party and arising out of or in connection with any damage or injury occurring in the Premises
or any acts or omission (including violations of Law) of Tenant, its trustees, managers, members, principals, beneficiaries, partners, officers, directors, employees and agents (the “Tenant Related Parties”) or any of
Tenant’s transferees, contractors or licensees, in or about the Premises, the Building or the Park. To the extent permitted pursuant to applicable Laws, Tenant hereby waives all claims against and releases Landlord and its trustees, managers,
members, principals, beneficiaries, partners, officers, directors, employees, Mortgagees (defined in Section 23) and agents (the “Landlord Related Parties”) from and against all claims, losses, cost, damages, any
liability or expense of whatever nature arising from injury, loss, accident or damage to any person or property, arising from or claimed to have arisen (a) from any accident, 

  
 13 

 
injury or damage whatsoever to any person, or to the property of any person, occurring in the Premises; (b) from the omission, fault, willful act, negligence or other misconduct of Tenant or
Tenant’s agents, employees, contractors, licensees or invitees, (c) in connection with Tenant’s use of the Premises or any business conducted therein or any work done or condition created in the Premises by Tenant, its agent,
employees or contractors, or anyone claiming by, through or under Tenant, (d) the failure of Tenant to perform and discharge its covenants and obligations under this Lease and, in any case, occurring after the Commencement Date (or such
earlier date as of which Tenant takes possession of the Premises) until the expiration of the Term of this Lease and thereafter so long as Tenant is in occupancy of any part of the Premises, (e) Force Majeure, (f) acts of
third parties, (g) the bursting or leaking of any tank, water closet, drain or other pipe, (h) the inadequacy or failure of any security or protective services, personnel or equipment, or (i) any matter not within
the reasonable control of Landlord. 
 13.02    Landlord agrees to indemnify, defend and hold the Tenant and the Tenant
Related Parties harmless against and from all Losses to a person or property which may be imposed upon, incurred by or asserted against the Tenant, or any of the Tenant Related Parties, by any third party arising out of, or in connection with, any
property damage or personal injury occurring at the Property, the Building, the Base Building or the Park, to the extent caused by (a) the negligent act or omission of the Landlord or Landlord Related Parties, or (b) the intentional
or willful misconduct of the Landlord or Landlord Related Parties. 
  

	14.	Tenant’s Insurance. 

 14.01    Tenant shall maintain the
following coverages in the following amounts: 
 (a)    Commercial General Liability Insurance covering claims of bodily
injury, personal injury and property damage arising out of Tenant’s operations and contractual liabilities, including coverage formerly known as broad form, on an occurrence basis, with minimum primary limits of $1,000,000 each occurrence and
$2,000,000 annual aggregate (and not more than $25,000 self-insured retention) and a minimum excess/umbrella limit of $3,000,000. 

(b)    Property insurance covering (i) all office furniture, business and trade fixtures, office equipment,
free-standing cabinet work, movable partitions, merchandise and all other items of Tenant’s property in the Premises installed by, for, or at the expense of Tenant (“Tenant’s Property”), and (ii) any
Leasehold Improvements installed by or for the benefit of Tenant, whether pursuant to this Lease or pursuant to any prior lease or other agreement to which Tenant was a party (“Tenant-Insured Improvements”). Such insurance shall be
written on a special cause of loss form for physical loss or damage, for the full replacement cost value (subject to reasonable deductible amounts) without deduction for depreciation of the covered items and in amounts that meet any co-insurance
clauses of the policies of insurance, and shall include coverage for damage or other loss caused by fire or other peril, including vandalism and malicious mischief, theft, water damage of any type, including sprinkler leakage, bursting or stoppage
of pipes, and explosion, and providing business interruption coverage for a period of one year. 
 (c)    Worker’s
Compensation and Employer’s Liability or other similar insurance to the extent required by Law. 

  
 14 

 14.02    Form of Policies. The minimum limits of insurance required to
be carried by Tenant shall not limit Tenant’s liability. Such insurance shall (i) be issued by an insurance company that has an A.M. Best rating of not less than A-VIII; (ii) be in form and content reasonably acceptable to Landlord; and (iii)
provide that it shall not be canceled or materially changed without thirty (30) days’ prior notice to Landlord (if commercially available, and otherwise such notice of cancelation or change shall be timely given by Tenant), except that ten (10)
days’ prior notice may be given in the case of nonpayment of premiums. Tenant’s Commercial General Liability Insurance shall (a) name Landlord, Landlord’s managing agent, and any other party designated by Landlord
(“Additional Insured Parties”) as additional insureds; and (b) be primary insurance as to all claims thereunder and provide that any insurance carried by Landlord is excess and
non-contributing with Tenant’s insurance. Landlord shall be designated as a loss payee with respect to Tenant’s Property insurance on any Tenant-Insured Improvements. Tenant shall deliver to
Landlord, on or before the Commencement Date and at least fifteen (15) days before the expiration dates thereof, certificates from Tenant’s insurance company on the forms currently designated “ACORD 28” (Evidence of Commercial
Property Insurance) and “ACORD 25-S” (Certificate of Liability Insurance) or the equivalent. Attached to the ACORD 25-S (or equivalent) there shall be an endorsement naming the Additional Insured Parties as additional insureds which
shall be binding on Tenant’s insurance company and Tenant or Tenant’s insurance agent shall notify each Additional Insured Party in writing at least thirty (30) days before any termination or material change to the policies (if
commercially available, and otherwise such notice of cancelation or change shall be timely given by Tenant), except that ten (10 days’ prior notice may be given in the case of nonpayment of premiums. If excess/umbrella insurance is provided,
any such certificate shall evidence coverage specifically with respect to the Property and the amount of coverage allocated thereto in compliance with Section 14.01 hereof. 

14.03    Tenant shall maintain such increased amounts of the insurance required to be carried by Tenant under this
Section 14, and such other types and amounts of insurance covering the Premises and Tenant’s operations therein, as may be reasonably requested by Landlord, but not in excess of the amounts and types of insurance then being required by
landlords of buildings comparable to and in the vicinity of the Building. 
 14.04    Landlord shall be responsible for
obtaining and maintaining insurance covering the Property, the Building and the Park in such coverage types and amounts as a reasonably prudent Landlord of similar property in the Burlington area would maintain on the Property, the Building, and the
Park. 
  

	15.	Subrogation. 

 Insofar as, and to the extent that, the following provision shall not make it impossible
to secure insurance coverage obtainable from responsible insurance companies doing business in the locality in which the Property is located (even though extra premium may result therefrom), Landlord and Tenant mutually agree that any property
damage insurance carried by either shall provide for the waiver by the insurance carrier of any right of subrogation against the other, and they further mutually agree that, with respect to any damage to property, the loss from which is covered by
insurance then being carried by them (or the property insurance which they are obligated to carry under this Lease, whether or not actually carried), respectively, the one carrying such insurance and suffering such loss waives and releases the other
of and from any and all claims with respect to such loss to the extent of the insurance proceeds paid with respect thereto. 

  
 15 

	16.	Casualty Damage. 

 16.01    If all or any portion of the Premises
becomes untenantable or inaccessible by fire or other casualty to the Premises or the Common Areas (collectively a “Casualty”), Landlord, with reasonable promptness, shall cause a general contractor selected by Landlord to provide
Landlord with a written estimate of the amount of time required, using standard working methods, to substantially complete the repair and restoration of the Premises and any Common Areas necessary to provide access to the Premises
(“Completion Estimate”). Landlord shall promptly forward a copy of the Completion Estimate to Tenant. If the Completion Estimate indicates that the Premises or any Common Areas necessary to provide access to the Premises cannot be
made tenantable within one hundred eighty (180) days from the date the repair is started, then either party shall have the right to terminate this Lease upon written notice to the other within ten (10) days after
Tenant’s receipt of the Completion Estimate. Tenant, however, shall not have the right to terminate this Lease if the Casualty was caused by the gross negligence or intentional misconduct of Tenant or any Tenant Related Parties. In addition,
Landlord, by notice to Tenant within ninety (90) days after the date of the Casualty, shall have the right to terminate this Lease if: (1) the Premises have been materially damaged and there is less than two
(2) years of the Term remaining on the date of the Casualty; (2) any Mortgagee requires that the insurance proceeds be applied to the payment of the mortgage debt; or (3) a material uninsured loss to the Building
or Premises occurs. 
 16.02    If this Lease is not terminated, Landlord shall promptly and diligently, subject to
reasonable delays for insurance adjustment or other matters beyond Landlord’s reasonable control, restore the Premises and Common Areas. Such restoration shall be to substantially the same condition that existed prior to the Casualty, except
for modifications required by Law or any other modifications to the Common Areas deemed desirable by Landlord. Notwithstanding Section 15, upon notice from Landlord, Tenant shall assign or endorse over to Landlord (or to any party designated by
Landlord) all property insurance proceeds payable to Tenant under Tenant’s insurance with respect to any Leasehold Improvements performed by or for the benefit of Tenant; provided if the estimated cost to repair such Leasehold Improvements
exceeds the amount of insurance proceeds received by Landlord from Tenant’s insurance carrier, the excess cost of such repairs shall be paid by Tenant to Landlord prior to Landlord’s commencement of repairs. Within fifteen
(15) days of demand, Tenant shall also pay Landlord for any additional excess costs that are determined during the performance of the repairs to such Leasehold Improvements. In no event shall Landlord be required to spend more for the
restoration of the Premises and Common Areas than the proceeds received by Landlord, whether insurance proceeds or proceeds from Tenant. If following any such casualty, the Premises or Tenant’s access thereto have not been restored to the
condition required hereunder by the later to occur of (a) the aforementioned one hundred eighty (180) day period or (b) the date that is thirty (30) days following the target completion date set forth
in the Completion Estimate, then Tenant shall have the right to terminate this Lease upon thirty (30) days’ written notice to Landlord, provided that such notice shall be rendered null and void and of no effect if Landlord
substantially completes the restoration within the thirty (30) day period following Tenant’s notice. Landlord shall not be liable for any inconvenience to Tenant, or injury to Tenant’s business resulting in any way from the
Casualty or the repair thereof. Provided that Tenant is not in Default, during any period of time that all or any portion of the Premises is rendered untenantable as a result of a Casualty, the Rent shall abate for the portion of the Premises that
is untenantable and not used by Tenant. 

  
 16 

	17.	Condemnation. 

 Either party may terminate this Lease if any material part of the Premises is taken or
condemned for any public or quasi-public use under Law, by eminent domain or private purchase in lieu thereof (a “Taking”). Landlord shall also have the right to terminate this Lease if there is a Taking of any portion of the
Building or Property which would have a material adverse effect on Landlord’s ability to profitably operate the remainder of the Building. The terminating party shall provide written notice of termination to the other party within forty-five
(45) days after it first receives notice of the Taking. The termination shall be effective as of the effective date of any order granting possession to, or vesting legal title in, the condemning authority. If this Lease is not terminated, Base
Rent and Tenant’s Pro Rata Share shall be appropriately adjusted to account for any reduction in the square footage of the Building or Premises. All compensation awarded for a Taking shall be the property of Landlord. The right to receive
compensation or proceeds is expressly waived by Tenant, provided, however, Tenant may file a separate claim for Tenant’s Property and Tenant’s reasonable relocation expenses, provided the filing of the claim does not diminish the amount of
Landlord’s award. If only a part of the Premises is subject to a Taking and this Lease is not terminated, Landlord, with reasonable diligence, will restore the remaining portion of the Premises as nearly as practicable to the condition
immediately prior to the Taking. In no event shall Landlord be required to spend more for the restoration of the Premises, Building or Property than the proceeds received by Landlord in connection with the applicable Taking. 

 

	18.	Events of Default. 

 In addition to any other default specifically described in this Lease, each of the
following occurrences shall be a “Default”: (a) Tenant’s failure to pay any portion of Rent when due; provided, however, such failure to pay Rent when due shall not constitute a Default unless and until Tenant fails to
cure any failure to pay Rent within five (5) days following Landlord’s written notice to Tenant of such late payment (“Monetary Default”), provided that Landlord shall not be required to provide more than two
(2) written notices to Tenant of any failure to pay Rent in any twelve (12) month period, and, at Landlord’s option, any additional failures during such 12-month period shall constitute an
immediate Monetary Default without notice; (b) Tenant’s failure (other than a Monetary Default or a default for which a shorter cure period is expressly provided herein) to comply with any term, provision, condition or covenant of this
Lease, if the failure is not cured within thirty (30) days after written notice to Tenant provided, however, if Tenant’s failure to comply cannot reasonably be cured within thirty (30) days, Tenant shall be allowed additional time
(not to exceed sixty (60) days) as is reasonably necessary to cure the failure so long as Tenant begins the cure within ten (10) days and diligently pursues the cure to completion; (c) Tenant permits a Transfer without Landlord’s
required approval or otherwise in violation of Section 11 of this Lease; or (d) Tenant or any Guarantor becomes insolvent, makes a transfer in fraud of creditors, makes an assignment for the benefit of creditors, admits in writing its
inability to pay its debts when due or forfeits or loses its right to conduct business; (e) the leasehold estate is taken by process or operation of Law. All notices sent under this Section shall be in satisfaction of, and not in addition to,
notice required by Law. 

  
 17 

	19.	Remedies. 

 19.01    Upon Default, Landlord shall have the right to
pursue any one or more of the following remedies: 
 (a)    Terminate this Lease by no less than two (2) days’
prior written notice delivered to Tenant, in which case Tenant shall immediately surrender the Premises to Landlord. If Tenant fails to surrender the Premises, Landlord, in compliance with Law, may enter upon and take possession of the Premises and
remove Tenant, Tenant’s Property and any party occupying the Premises. Tenant shall pay Landlord, on demand, all past due Rent and other losses and damages Landlord suffers as a result of Tenant’s Default, including, without limitation,
all Costs of Reletting (defined below) and any deficiency that may arise from reletting or the failure to relet the Premises. “Costs of Reletting” shall include all reasonable out of pocket costs and expenses incurred by
Landlord in reletting or attempting to relet the Premises, including, without limitation, legal fees and expenses, brokerage commissions, the cost of alterations and the value of other concessions or allowances granted to a new tenant. 

(b)    Terminate Tenant’s right to possession of the Premises and, in compliance with Law, remove Tenant,
Tenant’s Property and any parties occupying the Premises. Landlord may (but shall not be obligated to) relet all or any part of the Premises, without notice to Tenant, for such period of time and on such terms and conditions (which may include
concessions, free rent and work allowances) as Landlord in its absolute discretion shall determine. Landlord may collect and receive all rents and other income from the reletting. Tenant shall pay Landlord on demand all past due Rent, all Costs of
Reletting and any deficiency arising from the reletting or failure to relet the Premises. The re-entry or taking of possession of the Premises shall not be construed as an election by Landlord to terminate
this Lease. 
 19.02    In lieu of calculating damages under Section 19.01, Landlord may elect to receive as
damages the sum of (a) all Rent accrued through the date of termination of this Lease or Tenant’s right to possession, and (b) an amount equal to the total Rent that Tenant would have been required to pay for the remainder of the Term
discounted to present value at the Prime Rate (defined below) then in effect, minus the then present fair rental value of the Premises for the remainder of the Term as determined by Landlord, similarly discounted, after deducting all anticipated
Costs of Reletting. “Prime Rate” shall be the per annum interest rate publicly announced as its prime or base rate by a federally insured bank selected by Landlord in the state in which the Building is located. 

19.03    If Tenant is in Default of any of its non-monetary obligations under this Lease, Landlord shall have the right to
perform such obligations. Tenant shall reimburse Landlord for the cost of such performance upon demand together with an administrative charge equal to five percent (5%) of the cost of the work performed by Landlord. The repossession or re-entering
of all or any part of the Premises shall not relieve Tenant of its liabilities and obligations under this Lease. No right or remedy of Landlord shall be exclusive of any other right or remedy. Each right and remedy shall be cumulative and in
addition to any other right and remedy now or subsequently available to Landlord at Law or in equity. 
  

	20.	Limitation of Liability. 

 NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS LEASE, THE
LIABILITY OF LANDLORD (AND OF ANY SUCCESSOR LANDLORD) SHALL BE LIMITED TO LANDLORD’S INTEREST IN THE PROPERTY. TENANT SHALL LOOK SOLELY TO LANDLORD’S INTEREST IN THE PROPERTY FOR THE RECOVERY OF ANY JUDGMENT OR AWARD AGAINST LANDLORD UNDER
THIS LEASE, AND IN NO EVENT SHALL ANY LANDLORD RELATED PARTIES (EXCLUDING LANDLORD) HAVE ANY LIABILITY TO TENANT OR ANY OTHER PARTY FOR ANY ACTION OR OMISSION OF LANDLORD 

  
 18 

 
HEREUNDER. IN NO EVENT SHALL EITHER PARTY BE PERSONALLY LIABLE FOR ANY JUDGMENT OR DEFICIENCY UNDER THIS LEASE, NOR, EXCEPT AS EXPRESSLY SET FORTH HEREIN WITH RESPECT TO TENANT ONLY, SHALL EITHER
PARTY BE LIABLE TO THE OTHER FOR ANY LOST PROFIT, DAMAGE TO OR LOSS OF BUSINESS OR ANY FORM OF SPECIAL, PUNITIVE, INDIRECT OR CONSEQUENTIAL DAMAGE. BEFORE FILING SUIT FOR AN ALLEGED DEFAULT BY LANDLORD, TENANT SHALL GIVE LANDLORD AND THE
MORTGAGEE(S) WHOM TENANT HAS BEEN NOTIFIED HOLD MORTGAGES (DEFINED IN SECTION 23 BELOW), NOTICE AND REASONABLE TIME TO CURE THE ALLEGED DEFAULT. WITHOUT LIMITING THE FOREGOING, IN NO EVENT SHALL LANDLORD OR ANY MORTGAGEES OR LANDLORD RELATED PARTIES
EVER BE LIABLE FOR ANY CONSEQUENTIAL OR INCIDENTAL DAMAGES OR ANY LOST PROFITS OF TENANT. 
 21.    Relocation. Landlord,
at its expense, shall have the one-time right exercisable at any time before or during the Term upon one hundred twenty (120) days’ prior written notice to Tenant, to relocate Tenant from the Premises to alternative space within the
Park of reasonably comparable size, quality and utility (“Relocation Space”). Landlord shall use commercially reasonable efforts to accomplish as much of any such relocation as is reasonably practicable during non-business hours, so as to minimize unnecessary interruption to the business of the Tenant. Specifically, it is agreed that any such move shall be a so-called “white glove” move, with Tenant’s
employees being responsible only to pack their personal items on a given date, and upon completion of the move only to unpack such personal items at their new work stations/offices. To the extent reasonably practicable and subject to Tenant’s
good faith cooperation to effectuate same, any such relocation shall entail a Friday pack-up and weekend move, with the goal that Tenant shall be ready to occupy and operate in the Relocation Space as of the following Monday morning, subject to full
cooperation of Tenant’s IT and other organizational employees necessary to cause the same to occur in coordination with Landlord. From and after the date of the relocation, the Base Rent and Tenant’s Pro Rata Share shall be adjusted based
on the rentable square footage of the Relocation Space. Landlord shall pay Tenant’s reasonable costs of relocation, including all costs for moving Tenant’s furniture, equipment, supplies and other personal property, as well as the cost of
printing and distributing change of address notices to Tenant’s customers and one month’s supply of stationery showing the new address. Notwithstanding the foregoing, Landlord agrees that it shall not exercise the aforementioned relocation
right within the last twelve (12) months of the Term of this Lease. 
  

	22.	Holding Over. 

 If Tenant fails to surrender all or any part of the Premises at the termination of this
Lease, occupancy of the Premises after termination shall be that of a tenancy at sufferance. Tenant’s occupancy shall be subject to all the terms and provisions of this Lease, and Tenant shall pay an amount (on a per diem basis) equal to
(a) for the first thirty (30) days, 150% of the sum of the Base Rent and Additional Rent due for the period immediately preceding the holdover, and (b) thereafter, 200% of the sum of the Base Rent and Additional Rent due for the
period immediately preceding the holdover. No holdover by Tenant or payment by Tenant after the termination of this Lease shall be construed to extend the Term or prevent Landlord from immediate recovery of possession of the Premises by summary
proceedings or otherwise. In the event Tenant holds over more than thirty (30) days following the expiration or earlier termination of this Lease, Tenant shall be liable for all damages that Landlord suffers from the holdover, including lost
leases or penalties payable to replacement tenants. 

  
 19 

	23.	Subordination to Mortgages; Estoppel Certificate. 

 23.01    Tenant
accepts this Lease subject and subordinate to any mortgage(s), deed(s) of trust, deeds to secure debt, ground lease(s) or other lien(s) now or subsequently arising upon the Premises, the Building or the Property, and to renewals, modifications,
refinancings and extensions thereof (collectively referred to as a “Mortgage”). The party having the benefit of a Mortgage shall be referred to as a “Mortgagee”. This clause shall be self-operative, but upon request
from a Mortgagee or Landlord, Tenant shall execute, acknowledge as necessary and deliver to Landlord within fifteen (15) days after receipt thereof, a so-called subordination, non-disturbance and attornment agreement (“SNDA”) in favor of the Mortgagee on such Mortgagee’s standard form with such changes thereto as such Mortgagee shall agree to. As an
alternative, a Mortgagee shall have the right at any time to subordinate its Mortgage to this Lease. Upon request, Tenant, without charge, shall attorn to any successor to Landlord’s interest in this Lease. Landlord and Tenant shall each,
within twenty (20) days after receipt of a written request from the other, execute and deliver a commercially reasonable estoppel certificate to those parties as are reasonably requested by the other (including a Mortgagee or prospective
purchaser). Without limitation, such estoppel certificate may include a certification as to the status of this Lease, to Tenant’s knowledge the existence of any defaults and the amount of Rent that is due and payable. Notwithstanding anything
to the contrary contained herein, Landlord shall make a commercially reasonable effort to provide Tenant with a SNDA from any current or future Mortgagee, on the form provided by such Mortgagee with such commercially reasonable revisions as Tenant
may request and such Mortgagee shall agree to. 
 23.02    In the event Mortgagee enforces it rights under the Mortgage,
Tenant, at Mortgagee’s option, will attorn to Mortgagee or its successor; provided, however, that Mortgagee or its successor shall not be liable for or bound by (i) any payment of any Rent installment which may have been made more
than thirty (30) days before the due date of such installment, (ii) any act or omission of or default by Landlord under this Lease (but Mortgagee, or such successor, shall be subject to the continuing obligations of landlord
under the Lease to the extent arising from and after such succession to the extent of Mortgagee’s, or such successor’s, interest in the Property), (iii) any credits, claims, setoffs or defenses which Tenant may have against Landlord, or
(iv) any obligation to complete any construction or improvements for the benefit of Tenant or advance any tenant improvement allowance. Tenant, upon the reasonable request by Mortgagee or such successor in interest, shall execute and
deliver an instrument or instruments confirming such attornment. Notwithstanding the foregoing, if Mortgagee shall have entered into a non-disturbance agreement directly with the Tenant governing Tenant’s
obligations to attorn to Mortgagee or such successor in interest as landlord, the terms and provisions of such non-disturbance agreement shall supercede the provisions of this Section 23.02. 

 

	24.	Notice. 

 All demands, approvals, consents or notices (collectively referred to as a
“notice”) shall be in writing and delivered by hand or sent by overnight or same day courier service at the party’s respective Notice Address(es) set forth in Section 1;. Each notice shall be deemed to have been
delivered on the earlier to occur of actual delivery or the date on which delivery is refused, or one (1) day after notice is deposited with an overnight courier service in the manner described above. Either party may, at any time, change its
Notice Address (other than to a post office box address) by giving the other party written notice of the new address. Notice may be given by counsel for either party. 

  
 20 

	25.	Surrender of Premises. 

 On the Termination Date or earlier termination of this Lease or Tenant’s
right of possession, Tenant shall remove Tenant’s Property from the Premises, and quit and surrender the Premises to Landlord, broom clean, and in good order, condition and repair, ordinary wear and tear and damage which Landlord is obligated
to repair hereunder excepted. If Tenant fails to remove any of Tenant’s Property, or to restore the Premises to the required condition, on the Termination Date or earlier termination of this Lease or Tenant’s right to possession, Landlord,
at Tenant’s sole cost and expense, shall be entitled (but not obligated) to remove and store Tenant’s Property and/or perform such restoration of the Premises. Landlord shall not be responsible for the value, preservation or safekeeping of
Tenant’s Property. Tenant shall pay Landlord, upon demand, the expenses and storage charges incurred. If Tenant fails to remove Tenant’s Property from the Premises or storage, within ten (10) days after notice, Landlord may deem all
or any part of Tenant’s Property to be abandoned and, at Landlord’s option, title to Tenant’s Property shall vest in Landlord or Landlord may dispose of Tenant’s Property in any manner Landlord deems appropriate. 

 

	26.	Miscellaneous. 

 26.01    This Lease shall be interpreted and
enforced in accordance with the Laws of the state or commonwealth in which the Building is located and Landlord and Tenant hereby irrevocably consent to the jurisdiction and proper venue of such state or commonwealth. If any term or provision of
this Lease shall to any extent be void or unenforceable, the remainder of this Lease shall not be affected. If there is more than one Tenant or if Tenant is comprised of more than one party or entity, the obligations imposed upon Tenant shall be
joint and several obligations of all the parties and entities, and requests or demands from any one person or entity comprising Tenant shall be deemed to have been made by all such persons or entities. Notices to any one person or entity shall be
deemed to have been given to all persons and entities. 
 26.02    Tenant represents and warrants to Landlord, and
agrees, that (a) each individual executing this Lease on behalf of Tenant is authorized to do so on behalf of Tenant and (b) none of Tenant, Guarantor, if any, or its or their respective affiliates or partners nor to the best of
its knowledge, its or their members, shareholders or other equity owners or any of its or their respective employees, officers, directors, representatives or agents is (i) a person or entity with whom U.S. persons or entities are restricted
from doing business under regulations of the Office of Foreign Asset Control (“OFAC”) of the Department of the Treasury (including those named on OFAC’s Specially Designated and Blocked Persons List) or under any statute,
executive order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism) or other similar governmental action or (ii) in
violation of any Laws relating to terrorism or money laundering. 
 26.03    Landlord represents and warrants to Tenant,
and agrees, that: (a) each individual executing this Lease on behalf of Landlord is authorized to do so on behalf of Landlord, and (b) none of Landlord or its affiliates or partners nor to the best of its knowledge, its members,
shareholders or other equity owners or any of their respective employees, officers, directors, representatives or agents is (i) a person or entity with whom U.S. persons or entities are restricted from doing business under regulations of
OFAC (including those named on OFAC’s Specially Designated and Blocked Persons List) or under any statute, executive order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting

  
 21 

 
Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism) or other similar governmental action or (ii) in violation of any Laws relating to terrorism or money laundering.

 26.04    If Landlord retains an attorney or institutes legal proceedings due to Tenant’s Monetary Default, then
Tenant shall be required to pay Additional Rent in an amount equal to the reasonable attorneys’ fees and costs actually incurred by Landlord in connection therewith. Notwithstanding the foregoing, in any action or proceeding between Landlord
and Tenant, including any appellate or alternative dispute resolution proceeding, the prevailing party shall be entitled to recover from the non-prevailing party all of its costs and expenses in connection
therewith, including, but not limited to, reasonable attorneys’ fees actually incurred. Landlord and Tenant hereby waive any right to trial by jury in any proceeding based upon a breach of this Lease. No failure by either party to declare a
default immediately upon its occurrence, nor any delay by either party in taking action for a default, nor Landlord’s acceptance of Rent with knowledge of a default by Tenant, shall constitute a waiver of the default, nor shall it constitute an
estoppel. 
 26.05    Whenever a period of time is prescribed for the taking of an action by Landlord or Tenant (other
than any obligation of Tenant that can be performed by the payment of money e.g., the payment of the Security Deposit or Rent or the maintenance of insurance), the period of time for the performance of such action shall be extended by the number of
days that the performance is actually delayed due to strikes, acts of God, shortages of labor or materials, war, terrorist acts, pandemics, civil disturbances and other causes beyond the reasonable control of the performing party (“Force
Majeure”). 
 26.06    Tenant, within fifteen (15) days after written request, shall provide Landlord
with a current financial statement for Tenant. Landlord, however, shall not require Tenant to provide such information more than once per Fiscal Year, unless Landlord is requested to produce the information in connection with a proposed financing or
sale of the Building. Upon written request by Tenant, Landlord shall enter into a commercially reasonable confidentiality agreement covering any confidential information that is disclosed by Tenant. 

26.07    Landlord shall have the right to transfer and assign, in whole or in part, all of its rights and obligations
under this Lease and in the Building and Property. Upon transfer, Landlord shall be released from any further obligations hereunder and Tenant agrees to look solely to the successor in interest of Landlord for the performance of such obligations,
provided that any successor pursuant to a voluntary, third party transfer (but not as part of an involuntary transfer resulting from a foreclosure or deed in lieu thereof) shall have assumed Landlord’s obligations under this Lease from and
after the date of the transfer. 
 26.08    Landlord and Tenant each represents to the other that it has dealt directly
with and only with each of the Brokers (described in Section 1.11) as a broker, agent or finder in connection with this Lease. Tenant shall indemnify and hold Landlord and the Landlord Related Parties harmless from all claims of any other
brokers, agents or finders claiming to have represented Tenant in connection with this Lease. Landlord shall indemnify and hold Tenant and the Tenant Related Parties harmless from all claims of any brokers, agents or finders claiming to have
represented Landlord in connection with this Lease. 
 26.09    The expiration of the Term, whether by lapse of time,
termination or otherwise, shall not relieve either party of any obligations which accrued prior to or which may continue to accrue after the expiration or termination of this Lease. 

  
 22 

 26.10    Tenant may peacefully have, hold and enjoy the Premises free from
interference by Landlord or Landlord Related Parties subject to the terms of this Lease, provided Tenant pays the Rent and fully performs all of its covenants and agreements. 

26.11    This Lease does not grant any rights to light or air over or about the Building. Landlord excepts and reserves
exclusively to itself any and all rights not specifically granted to Tenant under this Lease. Landlord reserves the right to make changes to the Property (including adding or removing land therefrom), Building and Common Areas as Landlord deems
appropriate, including, without limitation, relocation of some or all of the surface parking spaces located on the Property to structured parking to be used in connection with the Property. This Lease constitutes the entire agreement between the
parties and supersedes all prior agreements and understandings related to the Premises, including all lease proposals, letters of intent and other documents. Neither party is relying upon any warranty, statement or representation not contained in
this Lease. This Lease may be modified only by a written agreement signed by an authorized representative of Landlord and Tenant. Wherever this Lease requires Landlord to provide a customary service or to act in a reasonable manner (whether in
incurring an expense, establishing a rule or regulation, providing an approval or consent, or performing any other act), this Lease shall be deemed also to provide that whether such service is customary or such conduct is reasonable shall be
determined by reference to the practices of owners of buildings that (i) are comparable to the Building in size, age, class, quality and location, and (ii) at Landlord’s option, have been, or are being prepared to be,
certified under the U.S. Green Building Council’s Leadership in Energy and Environmental Design (LEED) rating system or a similar rating system. 

26.12    Submission of this Lease by Landlord is not an offer to enter into this Lease but rather is a solicitation for
such an offer by Tenant. Neither party shall be bound by this Lease until both parties have executed and delivered the Lease to the other party. 

26.13    It is intended that all Rent payable by Tenant to Landlord, which includes all sums, charges, or amounts of
whatever nature to be paid by Tenant to Landlord in accordance with the provisions of this Lease, shall qualify as “rents from real property” within the meaning of both Sections 512(b)(3) and 856(d) of the Internal Revenue Code (the
“Code”), and the U.S. Department of Treasury Regulations promulgated thereunder (the “Regulations”). If Landlord, in its sole discretion, determines that there is any risk that all or part of any Rent shall not
qualify as “rents from real property” for the purposes of Section 512(b)(3) or 856(d) of the Code and the Regulations, Tenant agrees (i) to cooperate with Landlord by entering into such amendment or amendments to this
Lease (or any applicable sublease or assignment of this Lease) as Landlord reasonably deems necessary to qualify all Rent as “rents from real property,” and (ii) to permit an assignment of this Lease; provided, however, that
any adjustments required under this Section shall be made so as to produce the substantially equivalent (in economic terms) Rent as payable before the adjustment. 

26.14    If Landlord is advised by its counsel at any time that any part of the payments by Tenant to Landlord under this
Lease may be characterized as unrelated business income under the United States Internal Revenue Code and its regulations, then Tenant shall enter into any amendment proposed by Landlord to avoid such income, so long as the amendment does not create
adverse consequences for Tenant or otherwise require Tenant to make more payments or accept fewer services from Landlord, than this Lease provides. 

26.15    Tenant shall not record this Lease or any memorandum or notice of Lease. 

  
 23 

 26.16    This Lease may be executed in counterparts and shall constitute an
agreement binding on all parties notwithstanding that all parties are not signatories to the original or the same counterpart provided that all parties are furnished a copy or copies thereof reflecting the signature of all parties. Transmission of a
facsimile or by email of a pdf copy of the signed counterpart of the Lease shall be deemed the equivalent of the delivery of the original, and any party so delivering a facsimile or pdf copy of the signed counterpart of the Lease by email
transmission shall in all events deliver to the other party an original signature promptly upon request. 
 [Remainder of page
intentionally left blank] 

  
 24 

 Landlord and Tenant have executed this Lease under seal in two or more counterparts as of the day
and year first above written. 
  

			
	LANDLORD:
	
	NEEP INVESTORS HOLDINGS LLC, a Delaware limited liability company

 
			
		
	By:	 	 /s/  Stephen A. Kinsella

	Name:	 	 Stephen A. Kinsella

	Title:	 	 Authorized Officer

			
	
	TENANT:
	
	SCPHARMACEUTICALS INC., a Delaware corporation

 
			
		
	By:	 	 /s/  John H. Tucker

	Name:	 	 John H. Tucker

	Title:	 	 CEO

  
 25 

 EXHIBIT A-1 

OUTLINE AND LOCATION OF PREMISES 
  

 
 scPharmaceuticals, Inc. - 13,066 RSF 

2400 DISTRICT AVENUE - THIRD FLOOR - SUITE 310 - 

BURLINGTON, MA 

  
 A-1-1 

 EXHIBIT A-2 

LEGAL DESCRIPTION OF THE PROPERTY 

All that certain parcel of registered land with the buildings thereon situated on Burlington Mall Road and Executive Mall Road (formerly Entrance Road) in The
District in the Town of Burlington, Middlesex County, Commonwealth of Massachusetts and being known and numbered as 2400 District Avenue in said Burlington, all more particularly described as follows: 

That certain parcel of land situated in Burlington, Middlesex County, Massachusetts being more particularly shown as Lot 19 on Land Court Plan No. 31049-I filed with the Middlesex South Registry District of the Land Court in Registration Book 771, Page 47 with Certificate 128197. 

  
 A-2-1 

 EXHIBIT B 

EXPENSES AND TAXES 
  

	1.	Payments. 

 1.01    Tenant shall pay Tenant’s Pro Rata Share of
the amount, if any, by which Expenses (defined below) for each calendar year during the Term exceed Expenses for the Base Year (the “Expense Excess”) and also the amount, if any, by which Taxes (defined below) for each Fiscal
Year during the Term exceed Taxes for the Base Year (the “Tax Excess”). If Expenses or Taxes in any calendar year or Fiscal Year decrease below the amount of Expenses or Taxes for the Base Year, Tenant’s Pro Rata Share of
Expenses or Taxes, as the case may be, for that calendar year or Fiscal Year shall be $0. Landlord shall provide Tenant with a good faith estimate of the Expense Excess and of the Tax Excess for each calendar year or Fiscal Year during the Term. On
or before the first day of each month, Tenant shall pay to Landlord a monthly installment equal to one-twelfth of Tenant’s Pro Rata Share of Landlord’s estimate of both the Expense Excess and Tax
Excess. If Landlord determines that its good faith estimate of the Expense Excess or of the Tax Excess was incorrect by a material amount, Landlord may provide Tenant with a revised estimate. After its receipt of a revised estimate, Tenant’s
monthly payments shall be based upon the revised estimate. If Landlord does not provide Tenant with an estimate of the Expense Excess or the Tax Excess by the first day of a calendar year or Fiscal Year, as the case may be, Tenant shall continue to
pay monthly installments based on the previous year’s estimate(s) until Landlord provides Tenant with the new estimate. Upon delivery of the new estimate, an adjustment shall be made for any month for which Tenant paid monthly installments
based on the previous year’s estimate. Tenant shall pay Landlord the amount of any underpayment within thirty (30) days after receipt of the new estimate. Any overpayment shall be refunded to Tenant within thirty (30) days or credited
against the next due future installment(s) of Additional Rent. 
 1.02    As soon as is practical following the end of
each calendar year or Fiscal Year, as the case may be, Landlord shall furnish Tenant with a statement of the actual Expenses and Expense Excess and the actual Taxes and Tax Excess for the prior calendar year or Fiscal Year, as the case may be. If
the estimated Expense Excess or estimated Tax Excess for the prior calendar year or Fiscal Year, as the case may be, is more than the actual Expense Excess or actual Tax Excess for the prior calendar year or Fiscal Year, as the case may be, Landlord
shall either provide Tenant with a refund or apply any overpayment by Tenant against Additional Rent due or next becoming due, provided if the Term expires before the determination of the overpayment, Landlord shall refund any overpayment to Tenant
after first deducting the amount of Rent due. If the estimated Expense Excess or estimated Tax Excess for the prior calendar year or Fiscal Year, as the case may be, is less than the actual Expense Excess or actual Tax Excess, for such prior
calendar year or Fiscal Year, as the case may be, Tenant shall pay Landlord, within thirty (30) days after its receipt of the statement of Expenses or Taxes, any underpayment for the prior calendar year or Fiscal Year, as the case may be. 

 

	2.	Expenses. 

 2.01    “Expenses” means all
costs and expenses incurred in each calendar year in connection with operating, maintaining, repairing, and managing the Building, the Property, and the Park (as hereinafter provided for). Expenses include, without limitation: (a) all labor and
labor related costs, including wages, salaries, bonuses, taxes, insurance, uniforms, training, retirement plans, pension plans and other employee benefits; (b) management fees in an 

  
 B-1 

 
amount equal to three percent (3%) of the gross revenues from the Building; (c) the cost of equipping, staffing and operating an on-site and/or off-site management office for the Building, provided if the management office services one or more other buildings or properties, the shared costs and expenses of equipping, staffing and operating such management
office(s) shall be equitably prorated and apportioned between the Building and the other buildings or properties; (d) accounting costs; (e) the cost of services; (f) rental and purchase cost of parts, supplies, tools and equipment;
(g) insurance premiums and commercially reasonable deductibles; (h) electricity, gas and other utility costs; and (i) the amortized cost of capital improvements (as distinguished from repairs or replacement parts or components
installed in the ordinary course of business, all of which shall be includable in Expenses, but excluding in any event replacement of the roof, HVAC, parking lot or structure of the Building) made subsequent to the Base Year which are:
(1) intended to effect economies in the operation or maintenance of the Property and/or the Park, reduce current or future Expenses, or enhance the safety or security of the Property and/or the Park or its occupants, or enhance the
environmental sustainability of the Property’s operations, (2) replacements or modifications of nonstructural items located in the Base Building or Common Areas that are required to keep the Base Building or Common Areas in good condition,
or (3)required under any Law first in effect following the Commencement Date. The cost of capital improvements shall be amortized by Landlord over the lesser of the Payback Period (defined below) or the useful life of the capital improvement as
reasonably determined by Landlord in accordance with generally accepted accounting principles. The amortized cost of capital improvements may, at Landlord’s option, include actual or imputed interest at the rate that Landlord would reasonably
be required to pay to finance the cost of the capital improvement. “Payback Period” means the reasonably estimated period of time that it takes for the cost savings resulting from a capital improvement to equal the total cost
of the capital improvement. Landlord, by itself or through an affiliate, shall have the right to directly perform, provide and be compensated for any services under the Lease. If Landlord incurs Expenses for the Building or Property together with
one or more other buildings in the Park, whether pursuant to a reciprocal easement agreement, common area agreement or otherwise, the shared costs and expenses shall be equitably prorated and apportioned between the Building and Property and the
other buildings or properties in the Park, as applicable. 
 2.02    Expenses shall not include: the cost of capital
improvements (except as set forth above); depreciation; reserves, principal or interest payments of mortgage and other non-operating debts of Landlord; the cost of repairs or other work to the extent Landlord
is reimbursed by insurance or condemnation proceeds; costs in connection with leasing space in the Building, including advertising, legal and space planning expenses, brokerage commissions; lease concessions, rental abatements and construction
allowances granted to specific tenants; costs incurred in connection with the sale, financing or refinancing of the Building; fines, interest and penalties incurred due to the late payment of Taxes or Expenses; organizational expenses associated
with the creation and operation of the entity which constitutes Landlord; or any penalties or damages that Landlord pays to Tenant under this Lease or to other tenants in the Building under their respective leases, costs of Landlord’s
charitable or political contributions, or of artwork maintained at the Property to the extent in excess of reasonable and typical expenses for artwork at comparable buildings in the Burlington area, costs in connection with services (including
electricity), items or other benefits of a type which are not standard for the Property and which are not available to Tenant without specific charges therefor, but which are provided to another tenant or occupant of the Property whether or not such
other tenant or occupant is specifically charged therefor by Landlord, overhead and profit increment paid to Landlord or to subsidiaries or affiliates of Landlord for goods and/or services in or to the Property or Park to the extent the same exceeds
the costs of such goods and/or services 

  
 B-2 

 
rendered by unaffiliated third parties on a competitive basis, salaries, wages, benefits and other compensation paid to employees of Landlord at or above the level of property manager, asset
manager or similar title of persons who perform a management or administrative function as opposed to persons performing the ongoing maintenance or repair of the Property, the original construction costs of the Property or Park and renovation prior
to the date of the Lease and costs of correcting defects in such original construction or renovation, or the cost of the removal of any hazardous materials in, on or about the Property or Park. 

2.03    If at any time during a calendar year the Building and/or any other building in the Park, as applicable, is not at
least 95% occupied (or a service provided by Landlord to tenants of the Building (and/or any such other building) generally is not provided by Landlord to a tenant that provides such service itself, or any tenant of the Building (and/or any such
other building) is entitled to free rent, rent abatement or the like), Expenses shall, at Landlord’s option, be determined as if the Building (and/or any such other building) had been 95% occupied (and all services provided by Landlord to
tenants of the Building (and/or any such other building) generally had been provided by Landlord to all tenants, and no tenant of the Building (and/or any such other building) had been entitled to free rent, rent abatement or the like) during that
calendar year. If Expenses for a calendar year are determined as provided in the prior sentence, Expenses for the Base Year shall also be determined in such manner. Notwithstanding the foregoing, Landlord may calculate the extrapolation of Expenses
under this Section based on 100% occupancy and service so long as such percentage is used consistently for each year of the Term, including the Base Year. The extrapolation of Expenses under this Section shall be performed in accordance with the
methodology specified by the Building Owners and Managers Association. 
 Further, in the event that any item of Expenses for the Base Year
is unusually high due to unusual or extraordinary circumstances or events (for example, an unusually harsh winter which might result in higher than normal heating costs and/or snow and ice removal costs), such item shall be adjusted and reduced to
reflect the projected cost of what such item would have been had such unusual or extraordinary circumstances or events not arisen, and such adjusted amount shall be used in determining Expenses for the Base Year. 

3.    “Taxes” shall mean: (a) all real property taxes and other assessments on the Building and/or
Property, including, but not limited to, gross receipts taxes, assessments for special improvement districts and building improvement districts, governmental charges, fees and assessments for police, fire, traffic mitigation or other governmental
service of purported benefit to the Property, taxes and assessments levied in substitution or supplementation in whole or in part of any such taxes and assessments and the Property’s share of any real estate taxes and assessments under any
reciprocal easement agreement, common area agreement or similar agreement as to the Property; (b) all personal property taxes for property that is owned by Landlord and used in connection with the operation, maintenance and repair of the
Property; and (c) all costs and fees incurred in connection with seeking reductions in any tax liabilities described in (a) and (b), including, without limitation, any costs incurred by Landlord for compliance, review and appeal of tax
liabilities. Without limitation, Taxes shall be determined without regard to any “green building” credit and shall not include any income, capital levy, transfer, capital stock, gift, estate or inheritance tax. If a change in Taxes is
obtained for any year of the Term during which Tenant paid Tenant’s Pro Rata Share of any Tax Excess, then Taxes for that year will be retroactively adjusted and Landlord shall provide Tenant with a credit, if any, based on the adjustment.
Likewise, if a change is obtained for Taxes for the Base Year, Taxes for the Base Year shall be restated and the Tax Excess for all subsequent years shall be recomputed. Tenant shall pay Landlord the amount of Tenant’s Pro Rata Share of any
such increase in the Tax Excess within thirty (30) days after Tenant’s receipt of a statement from Landlord. 

  
 B-3 

	4.	Audit Rights. 

 Within ninety (90) days after receiving Landlord’s statement of
Expenses (or, with respect to the Base Year Expenses, within ninety (90) days after receiving Landlord’s initial statement of Expenses for the Base Year) (each such period is referred to as the “Review Notice Period”),
Tenant may give Landlord written notice (“Review Notice”) that Tenant intends to review Landlord’s records of the Expenses, Taxes and electricity to which the statement applies, and within thirty (30) days after
delivering the Review Notice to Landlord (such period is referred to as the “Request for Information Period”), Tenant shall send Landlord a written request identifying, with a reasonable degree of specificity, the particular
information Tenant desires to review (the “Request for Information”). Within a reasonable time (not to exceed fifteen (15) Business Days) after Landlord’s receipt of a timely Request for Information, Landlord shall forward
to Tenant, or make available for inspection on site at either the Building or at Landlord’s principal place of business, such records (or copies thereof) for the applicable calendar year, Fiscal Year (or Base Year, as applicable) that are
reasonably necessary for Tenant to conduct its review of the information identified in the Request for Information. Within sixty (60) days after any particular records are made available to Tenant (such period is referred to as the
“Objection Period”), Tenant shall have the right to give Landlord written notice (an “Objection Notice”) stating in reasonable detail any objection to (i) Landlord’s statement of Expenses for
that year which relates to the records that have been made available to Tenant and/or (ii) such records made available to Tenant, or the lack thereof. If Tenant provides Landlord with a timely Objection Notice, Landlord and Tenant shall work
together in good faith to resolve any issues raised in Tenant’s Objection Notice. If Landlord and Tenant determine that Expenses for the calendar year, Fiscal Year, and/or applicable billing period, are less than reported, Landlord shall
promptly provide Tenant with a credit against the next installment of Rent in the amount of the overpayment by Tenant, so that Tenant is reimbursed as quickly as possible. Likewise, if Landlord and Tenant determine that Expenses for the calendar
year, Fiscal Year, and/or applicable billing period, are greater than reported, Tenant shall pay Landlord the amount of any underpayment within thirty (30) days. If Tenant fails to give Landlord an Objection Notice with respect to any records
that have been made available to Tenant prior to expiration of the Objection Period applicable to the records which have been provided to Tenant, Tenant shall be deemed to have approved Landlord’s statement with respect to the matters reflected
in such records and shall be barred from raising any claims regarding the Expenses, Taxes, electricity or the Additional Rent payable during such periods. If Tenant fails to provide Landlord with a Review Notice prior to expiration of the Review
Notice Period or fails to provide Landlord with a Request for Information prior to expiration of the Request for Information Period described above, Tenant shall be deemed to have approved Landlord’s statement of applicable Expenses, applicable
Taxes, applicable electricity or applicable Additional Rent and shall be barred from raising any claims regarding the applicable Expenses, applicable Taxes, applicable electricity or applicable Additional Rent for that year, Fiscal Year and/or
applicable billing period. 
 If Tenant retains an agent to review Landlord’s records, the agent must be a CPA firm of individual CPA
licensed to do business in the state or commonwealth where the Property is located, and must be compensated solely on an hourly (and not contingency) basis. Tenant shall be solely responsible for all of Tenant’s costs, expenses and fees
incurred for the audit, and the fees charged cannot be based in whole or in part on a contingency basis. Landlord shall be solely responsible for all of Landlord’s costs, expenses and fees incurred for the audit.

  
 B-4 

 
The records and related information obtained by Tenant shall be treated as confidential, and applicable only to the Building and the Property by Tenant and its auditors, consultants and other
parties reviewing such records on behalf of Tenant (collectively, “Tenant’s Auditors”). In no event shall Tenant be permitted to examine Landlord’s records or to dispute any statement of Expenses unless Tenant has paid and
continues to pay (i) monthly the Base Rent, and (ii) monthly the regular recurring estimated payment of Expenses, Taxes and Electricity. In the event such audit discloses that Landlord’s statement overstated such actual costs and
expenses by five percent (5.0%) or more, then Landlord shall reimburse Tenant for the actual and reasonable cost of said audit within thirty (30) days of written demand therefor by Tenant. 

  
 B-5 

 EXHIBIT C 

WORK LETTER 
  

	1.	This Work Letter shall set forth the obligations of Landlord and Tenant with respect to the preparation of the Premises for Tenant’s occupancy. As used herein, “Landlord Work” shall mean the
work to be completed by Landlord, in a good and workmanlike manner, and in accordance with applicable Laws, to prepare the Premises for Tenant’s occupancy as described in the plan(s) and specifications set forth or referred to in Exhibit C-1 attached hereto (the “Plan”) and Exhibit C-2 attached hereto (the “Building Standard Specifications,” and
together with the Plan, the “Plans and Specifications”), which are incorporated herein. Landlord shall enter into a direct contract for the Landlord Work with a general contractor selected by Landlord in its sole discretion,
which may be Cranshaw Construction, an affiliate of Landlord. 

  

	2.	Landlord shall be responsible for the preparation of all initial and final architectural, electrical and mechanical construction drawings, plans and specifications (called “Plans”) necessary to
construct the Landlord Work in accordance with the conceptual floor plan for the Premises attached to this Lease as Exhibit C-1, which has been mutually approved by the parties. Tenant shall be
obligated to use diligent, good faith, and commercially reasonable efforts to respond to all requests from Landlord or Landlord’s architect for information necessary to prepare, revise or finalize the Plans as soon as is reasonably practicable,
but in any event within two (2) Business Days following written request therefor (unless a longer response period is specified in any such written request from Landlord or Landlord’s architect) in order to facilitate the timely preparation
of the Plans, and Tenant’s failure to timely respond as aforesaid shall constitute a Tenant Delay (on a day-for-day basis, beginning on the day following the day
set forth above for Tenant to respond, and ending on the day on which Tenant does in fact respond to the request for information) pursuant to the provisions of the Lease. 

 

	3.	On or prior to May 26, 2017, Landlord shall prepare and submit to Tenant final architectural, electrical and mechanical construction drawings, plans and specifications necessary to construct the Landlord Work in
accordance with Exhibit C-1. If Tenant shall request any changes to the Landlord Work following such date, in its sole discretion (each, a “Change Order”), Landlord shall cause
to be prepared any necessary revisions to the Plans and Specifications, and Tenant shall reimburse Landlord on demand for the cost of preparing such revisions. Landlord shall notify Tenant in writing of the estimated increased cost, if any, which
will be chargeable to Tenant by reason of such Change Order(s), and any Tenant Delay reasonably expected to result therefrom. Tenant shall, within three (3) Business Days after receiving Landlord’s estimate of the cost of the Change
Order(s), notify Landlord in writing whether it desires to proceed with such Change Order(s) and accept such increased cost and Tenant Delay, if any. In the absence of such written authorization, Landlord shall have the option to continue work on
the Premises disregarding the requested Change Order(s), or Landlord may elect to discontinue work on the Premises until it receives notice of Tenant’s decision plus payment of any such increased cost and acceptance by Tenant of such Tenant
Delay, in which event Tenant shall be responsible for any additional Tenant Delay in completion of Landlord Work (as reasonably determined by Landlord) resulting from such delay in written authorization. 

  
 C-1 

	4.	If Landlord shall be delayed in Landlord Work being Substantially Complete as a result of the occurrence of any of the following (a “Tenant Delay”): 

 

	 	(a)	Tenant’s failure to furnish information in accordance with this Work Letter or to respond to any request by Landlord for any approval or information within any time period prescribed, or if no time period is
prescribed, then within two (2) Business Days after such written request; or 

  

	 	(b)	Tenant’s request for materials, finishes or installations that have long lead times after having first been informed by Landlord that such materials, finishes or installations will cause a Delay; or

  

	 	(c)	Any Change Order(s) or failure to timely approve same; or 

  

	 	(d)	The performance or nonperformance by a person or entity employed by on or behalf of Tenant in the completion of any work in the Premises (all such work and such persons or entities being subject to prior approval of
Landlord); or 

  

	 	(e)	Any request by Tenant that Landlord delay the completion of any component of Landlord Work; or 

  

	 	(f)	Any breach or failure by Tenant in the performance of Tenant’s obligations under the Lease; or 

  

	 	(g)	Tenant’s failure to pay any amounts as and when due under this Work Letter; or 

  

	 	(h)	Any delay resulting from Tenant’s having taken possession of the Premises for any reason prior to Landlord Work being Substantially Complete; or 

 

	 	(i)	Any other delay reasonably and directly chargeable to Tenant, its agents, employees or independent contractors; 

then, for purposes of determining the Commencement Date, the date that Landlord Work shall be deemed to be Substantially Complete shall be the
day that Landlord Work would have been Substantially Complete absent any such Tenant Delay, all as reasonably determined by Landlord. 
  

	5.	This Work Letter shall not be deemed applicable to any additional space added to the original Premises at any time or from time to time, whether by any options under the Lease or otherwise, or to any portion of the
original Premises or any additions to the Premises in the event of a renewal or extension of the original Lease Term, whether by any options under the Lease or otherwise, unless expressly so provided in the Lease or any amendment or supplement to
the Lease. All capitalized terms used in this Work Letter but not defined herein shall have the same meanings ascribed to such terms in the Lease. 

[END OF EXHIBIT C] 

  
 C-2 

 EXHIBIT C-1 

PREMISES FIT PLAN 
  

 
  

	*	Countertop in pantry storage included as an add/alt. It is understood additional millwork is at the sole cost of the tenant. 

  
 C-1-1 

 EXHIBIT C-2 

BUILDING STANDARD SPECIFICATIONS 

THE DISTRICT BUILDING STANDARDS 
  

	1.	Walls 

  

	 	a.	2 V” metal studs with 5/8” GWB each side; taped, spackled and sanded 

  

	 	b.	Tenant Suite Demising walls - Construction full height to underside of deck with insulation 

  

	 	c.	Private offices and all interior suite walls - Construction height 6” above finished ceiling 

  

	 	d.	Conference Rooms - Construction full height to underside of deck with sound batt wall insulation at walls between rooms 

  

	 	e.	Server Rooms - Construction full height to underside of deck with sound batt wall insulation on all sides 

  

	 	f.	All walls must penetrate the ceiling a minimum of 6”. All demising partitions and corridor walls must extend completely and be sound insulated and fire taped; drywall and studs must extend to the underside
of the slab. All voids fire stopped. 

  

	2.	Floors 

  

	 	a.	Office interiors and reception - minimum 32 oz level loop commercial carpet, tile or broadloom Cost:($30/sy). Broadloom carpet is required at all 1st floors
suites. 

  

	 	b.	Storage, kitchens, break area, copy rooms - 12” x 12” VCT tile. 

  

	3.	Base 

  

	 	4”	Rubber base 

  

	4.	Doors & Sidelights 

 Entryway Doors - All tenant entry doors on the public corridors of
multi-tenant floors are to: 
  

	 	1.	Match existing doors of other tenants on the respective floors 

 OR 

 

	 	2.	Building Standard glass door with glass sidelight 

 Glass door hardware: 

Pivot hinges (top and bottom) 

Door pulls (both sides) per elevation 

Top and bottom rails at door 

Concealed closer (2 for pair of doors) 

Electromagnetic lock Schlage electronics m490 (Schlage electronics m492. for pair) 

Motion sensor - Schlage electronics scan ii 

Push to exit button - Schlage electronics 621rd-ex-da. 

Key switch device - Schlage electronics 653-05 for suite without card access/keypad 

Any Deviation from building standard must be approved by Property Management. Interior Suite Doors - all interior doors within
a tenant suite are to be 8’ high prefinished wood veneer solid core door. 
  

	 	i.	Office interiors 

 100, 700 and 2400 District Avenue 

Manufacturer: VT Industries 
  

			
	Style:	  	Heritage Collection Architectural Wood Door
		  	White Birch Veneer Plain Sliced, Grade A
		  	Five-Ply Flush Bonded Particle Door
		  	Color: TBD

  
 C-2-1 

	 	ii.	Frame - Hollow Metal, painted 

 Interior Sidelights - Drywall cased 18” frameless sidelight

  

	5.	Hardware and Locks 

  

	 	a.	All door hardware must conform to the building standard specification below. All Locks, including interior locks, must be building standard US 26D (626) Satin Chrome. 

 

			
	 Cylindrical lock:
	 	 Schlage ND series

		 	 Athens Lever Design

		 	626 Satin Chromium Plated

  

	 	b.	All mag locks must be tied into the Building’s Fire Alarm System. All mag locks must fail safe on fire alarm. 

  

	c.	All re-keying to be done at tenant’s expense with approved landlord vendor: 

Action Lock and Key 
 Office
number 781-229-9992 
 Email: nicole@alkinc.net 

17 Cambridge Street Burlington, MA 01803 

Keying as follow: 
 C145 Primus

 2400 District Avenue 
  

	6.	Ceilings 

  

	 	a.	Existing or 8’-6” ceiling height. 

  

	 	b.	All new ceilings are to be Armstrong Dune #1775 24”x24”, 9/16” beveled tegular tile, White 

  

	 	c.	All new ceiling grids must use Armstrong Suprafine XL 9/16” exposed tee system, White 

  

	 	d.	At initial walkthrough evaluate above ceiling conditions for open ceiling concept and inform landlord of findings and/or challenges 

  

	7.	Paint 

  

	 	a.	(1) coat primer, (2) coats finish latex, eggshell finish at all gyp. walls Millwork 

  

	8.	Millwork 

  

	 	a.	Plastic laminated base and upper cabinets as indicated on Tenant Space plans in kitchen area and work areas 

  

	 	b.	Exclusions; Reception desk 

  

	9.	Lighting 

  

	 	a.	General: if parabolic fixtures exist within suite, they must be replaced with either T5 or LED fixtures as follow: 

  

	 	i.	2’x4’ recessed direct/indirect basket fixture Focal Point Luna FLU-24-PS-3-T5-G-WH (3) T-5; 3500k 

 

	 	ii.	2’x2’ recessed direct/indirect basket fixture Focal Point Luna FLU-22-PS-2-T5-G-WH (2) T-5; 3500k 

 

	 	iii.	Downlight: Spectrum Lighting: SGE6LEDOS-20L-35K-DS102-MW

  

	 	iv.	Wallwasher: Spectrum Lighting: SGW6LEDOS-20L-35K-DS102-MW

  

	 	v.	Exit Sign: Edge-Lit mirror back LED recessed mount, brushed aluminimun with red lettering, emergency battery and self diagnostics. Arrows as required by location. Lithonia
Lighting: LRP X RMR X 120/277 EL/N 

  
 C-2-2 

	 	b.	Illumination levels as required by State of Massachusetts Building Energy Code 

  

	 	c.	Standard switching motion sensors to comply with State of Massachusetts Building Energy Code 

  

	 	d.	All new light switches to be white plate and white device. If existing devices are to remain in 50% of suite they must match existing 

 

	 	e.	Light Fixtures can be secured to structure by jack chain only. No tie wires of any kind shall be allowed 

  

	10.	Electrical 

  

	 	a.	Private Offices - (2) duplex outlet receptacles 

  

	 	b.	Open Office Areas - Convenience duplex outlet receptacles as required. 

  

	 	c.	All new electrical receptacles to be white plate and white device. If existing devices are to remain in 50% of suite they must match existing 

 

	 	d.	Wiring within all closets, or any exposed interior area shall be EMT conduit from any enclosure to a minimum of 6” above ceiling 

 

	 	e.	All outlet must be labelled with panel and circuit numbers 

  

	 	f.	All floor coring must be done off hours and notification must be sent in writing to landlord 2 weeks prior to date of work 

  

	11.	Voice and Data 

  

	 	a.	Private offices - (1) junction box w/pull string 

  

	 	b.	Open Office Area - Junction box w/pull string as required by Tenant’s Layout 

  

	 	c.	Tenant is responsible for all Voice, Data and A/V distribution 

  

	12.	HVAC 

  

	 	a.	During construction: 

  

	 	i.	Negative air units need to be in place and operating at all times 

  

	 	ii.	All returns must be covered with filter media at all times 

  

	 	b.	Tenant is responsible for installation, repairs, maintenance and replacement of all supplemental HVAC units dedicated to their Premises 

 

	 	c.	Thermostat locations as required by zone 

  

	 	d.	Return Air through plenum 

  

	 	e.	Approved Balancing Contractors at The District 

  

	 	i.	J.F. Coffey Associates 

 Martin Monaghan 

martin@jfcoffey.com 
 (617) 769-9901 
 61 Willard Street 

Quincy, MA 02169 
  

	 	ii.	E.L. Barrett 

 Ed Barrett 

m.(617) 770-9075 

b. (617) 770-9990 

1147 Hancock Street, Suite 201 

Quincy, MA 02169 
  

	13.	Plumbing 

  

	 	a.	According to plan: including distribution, insulation, electrical water heater, vents and drains 

  
 C-2-3 

	 	b.	All water heaters shall have an automatic leak detector and water shutoff included as part of install 

  

	 	c.	All hot water heaters shall have drain pans 

  

	 	d.	Check life of existing water heater in premises and replace as required 

  

	 	e.	If a sink has an ejector pump it must be replaced 

  

	 	f.	Tenant is responsible for the cost of valved and capped cold water lines required for tenant’s equipment (ie. refrigerator, coffee machine, filtration system, etc.) 

 

	 	i.	Tenant is responsible for all equipment 

  

	 	g.	Tenant is responsible for all repairs and replacement of water heaters that are dedicated to their premises 

  

	14.	Fire Protection 

  

	 	a.	Interior hydraulically calculation fire protection sprinkler system per State of Massachusetts Building Code. 

  

	 	b.	Fully sprinklered 

  

	 	c.	Sprinkler heads are to be concealed type, centered in ceiling tile. 

  

	15.	Fire Alarm 

  

	 	a.	As required by State of Massachusetts Building Code. 

  

	 	b.	Testing and programming by companies listed below in respective buildings. 

 Testing by RB
Allen and fire alarm company on record for testing 
 RB Allen Contact Info 

Jack Hall 
 Office number 603-964-8140 
 Email: jackhall@rballen.com 

Programming by RB Allen 
 RB
Allen Contact Info 
 Jack Hall 

Office number 603-964-8140 

Email: jackhall@rballen.com 
  

	16.	Security 

  

	 	a.	Tenant is responsible for installing any and all security systems, alarms, controls and distribution dedicated to their Premises. Security system must be approved by Landlord PRIOR to installation. 

 

	17.	Fireproofing 

  

	 	a.	In event of any structural steel is exposed at 700, 800 and 2400 District, thorough fireproofing shall be required as part of contractor’s scope of work. 

 

	 	b.	Subcontractors engaged to replace fireproofing materials must be licensed by the manufacturer and have prior experience in at least two projects of similar size and scope. 

 

	 	c.	All structural elements (columns, beams, etc.) must have an application to afford three hours of fire resistance. Floors and decking are to be two hour rated. 

  
 C-2-4 

 EXHIBIT D 

COMMENCEMENT LETTER 
  

			
	Date	  	                    2017
	Tenant	  	ScPharmaceuticals Inc.
	Address	  	2400 District Avenue, Suite 310
	 	  	Burlington, Massachusetts 01803

  

	Re:	Commencement Letter with respect to that certain Lease dated as of                     , 2017, by and between NEEP
Investors Holdings LLC, as Landlord, and ScPharmaceuticals Inc., as Tenant, for 13,066 rentable square feet on the 3rd floor of the Building located at 2400 District
Avenue, Burlington, Massachusetts 01803. 

 Dear
                    : 
 In accordance
with the terms and conditions of the above referenced Lease, Tenant hereby confirms and agrees that it has accepted possession of the Premises with the Landlord Work having been completed, and acknowledges as follows: 

 

	 	1.	The Commencement Date of the Lease is                     ; 

 

	 	2.	The Rent Commencement Date of the Lease is                     ; and 

 

	 	3.	The Termination Date of the Lease is                     . 

Please acknowledge the foregoing and your acceptance of possession by signing all 3 counterparts of this Commencement Letter in the space
provided and returning 2 fully executed counterparts to my attention. Tenant’s failure to execute and return this letter, or to provide written objection to the statements contained in this letter, within 10 days after the date of this letter
shall be deemed an approval by Tenant of the statements contained herein. 
 Sincerely, 

 

			
	NEEP Investors Holdings LLC
		
	By:	 	  

		 	Authorized Signatory

 Acknowledged and Accepted: 
  

					
	        	 	Tenant:	 	ScPhamaceuticals Inc.
			
		 	By:	 	                                      
                      
		 	Name:	 	                                      
                      
		 	Title:	 	                                      
                      
		 	Date:	 	                                      
              ,2017

  
 D-1 

 EXHIBIT E 

BUILDING RULES AND REGULATIONS 

Capitalized terms used but not defined herein shall have the meanings given in the Lease. 

The following rules and regulations shall apply, where applicable, to the Premises, the Building, the parking facilities (if any), the
Property and the appurtenances. In the event of a conflict between the following rules and regulations and the remainder of the terms of the Lease, the remainder of the terms of the Lease shall control. 

1.    Sidewalks, doorways, vestibules, halls, stairways and other similar areas shall not be obstructed by Tenant or used
by Tenant for any purpose other than ingress and egress to and from the Premises. No rubbish, litter, trash, or material shall be placed, emptied, or thrown in those areas. At no time shall Tenant permit Tenant’s employees to loiter in Common
Areas or elsewhere about the Building or Property. 
 2.    Plumbing fixtures and appliances shall be used only for the
purposes for which designed and no sweepings, rubbish, rags or other unsuitable material shall be thrown or placed in the fixtures or appliances. 

3.    No signs, advertisements or notices shall be painted or affixed to windows, doors or other parts of the Building,
except those of such color, size, style and in such places as are first approved in writing by Landlord. All tenant identification and suite numbers at the entrance to the Premises, shall be installed by Landlord, at Landlord’s cost and
expense, using the standard graphics for the Building. Except in connection with the hanging of lightweight pictures and wall decorations, no nails, hooks or screws shall be inserted into any part of the Premises or Building except by the Building
maintenance personnel without Landlord’s prior approval, which approval shall not be unreasonably withheld. Landlord shall make one space in the Building’s directory located in the lobby of the Building available to identify Tenant’s
name. Landlord shall make any revisions as Tenant requests in and to the initial listing after the Commencement Date, provided Tenant shall pay Landlord Landlord’s reasonable charge for such revision. 

4.    Landlord may provide and maintain in the first floor (main lobby) of the Building an alphabetical directory board or
other directory device listing tenants and no other directory shall be permitted unless previously consented to by Landlord in writing. 

5.    Tenant shall not place any lock(s) on any door in the Premises or Building without Landlord’s prior written
consent, which consent shall not be unreasonably withheld, and Landlord shall have the right at all times to retain and use keys or other access codes or devices to all locks within and into the Premises. A reasonable number of keys to the locks on
the entry doors in the Premises shall be furnished by Landlord to Tenant at Landlord’s cost and Tenant shall not make any duplicate keys. All keys shall be returned to Landlord at the expiration or early termination of the Lease. 

6.    All contractors, contractor’s representatives and installation technicians performing work in the Building
shall be subject to Landlord’s prior approval, which approval shall not be unreasonably withheld, and shall be required to provide certificates of insurance as required under Section 9.03 of this Lease and comply with Landlord’s
standard rules, 

  
 E-2 

 
regulations, policies and procedures, which may be revised from time to time. Landlord has no obligation to allow any particular telecommunication service provider to have access to the Building
or to the Premises. If Landlord permits access, Landlord may condition the access upon the payment to Landlord by the service provider of fees assessed by Landlord in Landlord’s sole discretion. 

7.    Movement in or out of the Building of furniture or office equipment, or dispatch or receipt by Tenant of merchandise
or materials requiring the use of elevators, stairways, lobby areas or loading dock areas, shall be performed in a manner and restricted to hours reasonably designated by Landlord. Tenant shall obtain Landlord’s prior approval by providing a
detailed listing of the activity, including the names of any contractors, vendors or delivery companies, which approval shall not be unreasonably withheld, conditioned or delayed. Tenant shall assume all risk for damage, injury or loss in connection
with the activity and shall provide appropriate certificates of insurance covering any such activities as may be required by Landlord. 

8.    Landlord shall have the right to approve the weight, size, or location of heavy equipment or articles in and about
the Premises, which approval shall not be unreasonably withheld; provided that approval by Landlord shall not relieve Tenant from liability for any damage in connection with such heavy equipment or articles. 

9.    Corridor doors, when not in use, shall be kept closed. 

10.    Tenant shall not: (a) make or permit any improper, objectionable or unpleasant noises or odors in the
Building, or otherwise interfere in any way with other tenants or persons having business with them; (b) solicit business or distribute or cause to be distributed, in any portion of the Building, handbills, promotional materials or other
advertising; or (c) conduct or permit other activities in the Building that might, in Landlord’s sole opinion, constitute a nuisance. 

11.    No animals, except those assisting handicapped persons, shall be brought into the Building or kept in or about the
Premises. 
 12.    No inflammable, explosive or dangerous fluids or substances shall be used or kept by Tenant in the
Premises, Building or about the Property, except for those substances as are typically found in similar premises used for general office purposes and are being used by Tenant in a safe manner and in accordance with all applicable Laws. Tenant shall
not, without Landlord’s prior written consent, use, store, install, spill, remove, release or dispose of, within or about the Premises or any other portion of the Property, any asbestos-containing materials or any solid, liquid or gaseous
material now or subsequently considered toxic or hazardous under the provisions of 42 U.S.C. Section 9601 et seq., M.G.L. c. 21C, M.G.L. c. 21E or any other applicable environmental Law which may now or later be in effect. Tenant shall comply
with all Laws pertaining to and governing the use of these materials by Tenant and shall remain solely liable for the costs of abatement and removal. 

13.    Tenant shall not use or occupy the Premises in any manner or for any purpose which might injure the reputation or
impair the present or future value of the Premises or the Building. Tenant shall not use, or permit any part of the Premises to be used for lodging, sleeping or for any illegal purpose. 

  
 E-3 

 14.    Tenant shall not take any action which would violate Landlord’s
labor contracts or which would cause a work stoppage, picketing, labor disruption or dispute or interfere with Landlord’s or any other tenant’s or occupant’s business or with the rights and privileges of any person lawfully in the
Building (“Labor Disruption”). Tenant shall take the actions necessary to resolve the Labor Disruption, and shall have pickets removed and, at the request of Landlord, immediately terminate any work in the Premises that gave rise to
the Labor Disruption, until Landlord gives its written consent for the work to resume. Tenant shall have no claim for damages against Landlord or any of the Landlord Related Parties nor shall the Commencement Date of the Term be extended as a result
of the above actions. 
 15.    Tenant shall not install, operate or maintain in the Premises or in any other area of
the Building, electrical equipment that would overload the electrical system beyond its capacity for proper, efficient and safe operation as determined solely by Landlord. Tenant shall not furnish cooling or heating to the Premises, including,
without limitation, the use of electric or gas heating devices, without Landlord’s prior written consent. Tenant shall not use more than its proportionate share of telephone lines and other telecommunication facilities available to service the
Building. 
 16.    Tenant shall not operate or permit to be operated a coin or token operated vending machine or
similar device (including, without limitation, telephones, lockers, toilets, scales, amusement devices and machines for sale of beverages, foods, candy, cigarettes and other goods), except for machines for the exclusive use of Tenant’s
employees and invitees. 
 17.    Bicycles and other vehicles are not permitted inside the Building or on the walkways
outside the Building, except in areas designated by Landlord. 
 18.    Landlord may from time to time adopt systems and
procedures for the security and safety of the Building and Property, their occupants, entry, use and contents. Tenant, its agents, employees, contractors, guests and invitees shall comply with Landlord’s systems and procedures. 

19.    Landlord shall have the right to prohibit the use of the name of the Building or any other publicity by Tenant that
in Landlord’s sole opinion may impair the reputation of the Building or its desirability. Upon written notice from Landlord, Tenant shall refrain from and discontinue such publicity immediately. 

20.    Neither Tenant nor its agents, employees, contractors, guests or invitees shall smoke or permit smoking in the
Common Areas, unless a portion of the Common Areas have been declared a designated smoking area by Landlord, nor shall the above parties allow smoke from the Premises to emanate into the Common Areas or any other part of the Building. Landlord shall
have the right to designate the Building (including the Premises) as a nonsmoking building. 
 21.    Landlord shall
have the right to designate and approve standard window coverings for the Premises and to establish rules to assure that the Building presents a uniform exterior appearance. Tenant shall ensure, to the extent reasonably practicable, that window
coverings are closed on windows in the Premises while they are exposed to the direct rays of the sun. 

  
 E-4 

 22.    Deliveries to and from the Premises shall be made only at the times in
the areas and through the entrances and exits reasonably designated by Landlord. Tenant shall not make deliveries to or from the Premises in a manner that might interfere with the use by any other tenant of its premises or of the Common Areas, any
pedestrian use, or any use which is inconsistent with good business practice. 
 23.    The work of cleaning personnel
shall not be hindered by Tenant after 5:30 P.M., and cleaning work may be done at any time when the offices are vacant. Windows, doors and fixtures may be cleaned at any time. Tenant shall provide adequate waste and
rubbish receptacles to prevent unreasonable hardship to the cleaning service. 
 24.    Tenant shall cause its
employees, agents, invitees and contractors to comply with Landlord’s smoking policy for the Building and the Park, which may be communicated to Tenant from time to time (e.g. smokers to use only designated outside area(s)). 

25.    Tenant shall at all times cause its employees, agents, invitees and contractors to obey posted speed limits within
the Park. 

  
 E-5 

 EXHIBIT F 

ADDITIONAL PROVISIONS 
  

	I.	PARKING. 

 Landlord agrees that during the term of this Lease, Tenant shall have the right (at no
additional charge) to use forty-three (43) non-designated parking spaces (based on a ratio of 3.25 spaces per 1,000 rentable square feet of the Premises) as may be reasonably necessary to accommodate
officers, employees, guests, invitees and clients, in connection with the operation of its business following the Commencement Date. Tenant’s parking spaces shall be located in the areas designated at the Park by Landlord from time to time in
its sole discretion, including, without limitation, some or all of such spaces in the parking garage in the Park. At Landlord’s election and at no cost to Tenant, Landlord may designate parking spaces for exclusive use by Tenant and other
tenants of the Property and may install signage or implement a pass or sticker system to control parking use, and may employ valet parking to meet the requirements of this Section. To the extent applicable to Tenant’s use of the parking spaces,
the provisions of the Lease shall apply, including rules and regulations of general applicability from time to time promulgated by Landlord. 

  
 F-1EX-10.6

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

Exhibit 10.6 

LICENSE AGREEMENT 
 This
LICENSE AGREEMENT (this “Agreement”) is made and entered into as of June 29, 2015 (the “Effective Date”), by and among scPharmaceuticals Inc., having an address at 131 Hartwell Avenue, Suite 215,
Lexington, MA 02421 (“scPharma”) and Sensile Medical AG, having an address at Fabrikstrasse 10, CH-4614 Hägendorf, Switzerland (“Sensile Med”) and Sensile Holding AG
(“Sensile Holding”) and Sensile Patent AG (“Sensile Patent”), both having an address at Zuger Strasse 76b, CH-6340, Baar, Switzerland (Sensile Med, Sensile Holding and Sensile
Patent together in any combination, “Sensile”) (each of scPharma, Sensile Med, Sensile Holding and Sensile Patent, a “Party” and, collectively, the “Parties”), 

WITNESSETH 
 WHEREAS,
the Parties have executed a Strategic Partnership Agreement dated March 18, 2013 (the “Original Partnership Agreement”) and an amendment to the Original Partnership Agreement dated January 31, 2014 (the Original
Partnership Agreement as amended shall be referred to herein as the “Partnership Agreement”); 
 WHEREAS, the
Parties have executed a Device Development Agreement pertaining to a Drug/Device combination for loop diuretics dated March 22, 2013 (the “Original Development Agreement”), an amendment to the Original Development Agreement on
July 29th 2013, and a second amendment on February 17, 2014 (the Original Development Agreement as amended shall be referred to herein as the “Development Agreement”); 

WHEREAS, scPharma and Sensile Holding have executed a Development Option Agreement dated June 24, 2013 (“Original Option
Agreement”) and a Notice of Exercise of Option to Develop and Commercialize dated October 31, 2013 (“Notice of Exercise”) (the Original Option Agreement together with the Notice of Exercise shall be referred to herein
as the “Option Agreement”); 
 WHEREAS, the Parties have executed an Omnibus Amendment dated February 28, 2014,
amending and clarifying provisions in said agreements; 
 WHEREAS, the Partnership Agreement together with the Development Agreement
and Option Agreement, as amended by the Omnibus Amendment, shall be referred to herein as the “Original Agreements”; 

WHEREAS, Sensile is the developer and manufacturer of advanced drug delivery devices, and owns certain technology relating to the Pump
(as defined herein) and related mechanisms which collectively constitute a Device (as defined herein); 
 WHEREAS, scPharma is a
biotechnology company developing biopharmaceutical drug/device products; and 
 WHEREAS, the Parties are collaborating on the
development and commercialization of certain drug/device combinations with scPharma contributing Drug-related development and Sensile contributing Device-related development. 

 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other
good and valuable consideration, the sufficiency of which is acknowledged, the Parties hereby agree as follows: 

1.    DEFINITIONS 

The following terms shall have the meanings assigned to them below for purposes of this Agreement: 

“Affiliate” means any corporation or non-corporate entity, which directly or
indirectly controls, is controlled by, or is under common control with a Party. A corporation or noncorporate entity shall be regarded as in control of another corporation if it owns or directly or indirectly controls at least fifty percent (50%) of
the voting stock of the other corporation or (i) in the absence of the ownership of at least fifty percent (50%) of the voting stock of a corporation or (ii) in the case of a non-corporate entity,
the power to direct or cause the direction of the management and policies of such corporation or non-corporate entity, as applicable. 

“Clinical Trial” means a clinical study designed to investigate the safety, efficacy, economic or other aspects of a
treatment, which may be conducted in support of Regulatory Approval, for marketing purposes or to investigate the utility in a particular clinical setting. For purposes of clarity, Clinical Trials include phase I, phase II, phase III or phase IV
clinical trials. 
 “Confidential Information” means, subject to the exceptions set forth in the following sentence, any
information or data, regardless of whether it is in tangible form, disclosed by either Party (the “Disclosing Party”) that the Disclosing Party has either marked as confidential or proprietary, or has identified in writing as
confidential or proprietary within thirty (30) days of disclosure to the other Party (the “Receiving Party”); provided, however, that information or data related to or regarding a Disclosing Party’s business plans,
strategies, technology, research and development, current and prospective customers, and products or services shall be deemed Confidential Information of the Disclosing Party even if not so marked or identified, unless such information is the
subject of any of the exceptions set forth in the following sentence. Information and data will not be deemed Confidential Information hereunder if such information: (a) is known to the Receiving Party prior to receipt from the Disclosing Party
directly or indirectly from a source other than one having an obligation of confidentiality to the Disclosing Party; (b) becomes known (independently of disclosure by the Disclosing Party) to the Receiving Party directly or indirectly from a
source other than one having an obligation of confidentiality to the Disclosing Party; (c) becomes publicly known or otherwise ceases to be secret or confidential, except through a breach of this Agreement by the Receiving Party; or (d) is
independently developed by the Receiving Party without use of the Disclosing Party’s Confidential Information. 

“Control” or “Controlled” means that a party has the right, without needing to seek further consent, or to
otherwise breach any obligation upon it, to transfer, disclose, license or make available to another the relevant right or asset (as the context requires). 

“Cover” means with respect to any product, component or process, that an Intellectual Property Right (or, if such
Intellectual Property Right is a Patent Right, that a valid claim of such Patent Right) owned or Controlled by a Party would, absent a license thereunder or ownership thereof, be infringed or misappropriated by the use, development, having
developed, making, having made, sell, having sold, offering for sale, importing, having imported, exporting, having exported or otherwise exploiting or having exploited of a product, component or process in the

  
 2 

 
Territory in the Field of Use, provided however, that in determining whether a valid claim that is a claim of a pending patent application would be infringed, it shall be treated as if issued as
then currently prosecuted. Cognates of the word “Cover” shall have correlative meanings. 
 “Develop” means to
discover, research, design or otherwise develop the Device or a process to produce the Device, or perform regulatory activities or production planning for the Device, in accordance with a Development Plan. “Development” means any
and all activities directed to the discovery, research, design, development, regulatory activities and production planning of the Device, as mutually agreed upon by the Parties in a Development Plan. 

“Development Plan” means a plan containing the description of the Development activities for the Device. 

“Device” means a mini drug delivery pump device that includes a Pump, Disposable Component and Reusable Component and other
components. 
 “Disposable Component” shall mean a device component comprised of the Pump, fluid path and other components,
that is designed to be (i) combined with the Reusable Component, (ii) suitable for single-use administration of a Drug and (iii) discarded or recycled after such use. 

“Drug” means any biopharmaceutical product that scPharma wishes to develop for subcutaneous administration by means of a
drug/device combination. 
 “Excluded Field” means (i) pharmaceutical products for the treatment of diabetes based on
the SenseCore Technology, (ii) use with dopaminergic therapy based on the SenseCore Technology, (iii) oncology drugs and biosimilars thereof based on the SenseCore Technology, (iv) to the extent exclusivity has been granted to a Third
Party under an existing agreement with Sensile as of the Effective Date of the Omnibus Amendment, diabetes, neurology, pain management, general infusion, enteral nutrition, dopaminergic therapy, oncology and neonatology, and (v) to the extent
exclusivity may be granted to a Third Party by Sensile in the future, products outside the Exclusive Areas. 
 “Exclusive
Areas” means Generics in the field of 
 (i)    loop diuretics, 

(ii)    glycopeptide antibiotics, 

(iii)    cephalosporins, 

(iv)    inotropes, vasopressors, anti-arrythmics, heart failure medications and calcium channel blockers,
in each case, for cardiovascular diseases, 
 (v)    antibiotics, antifungals and antivirals, in each
case, for infectious diseases, 
 (vi)    infertility medications and iron chelation therapies, in each
case, for hematology or infertility that are suitable for subcutaneous administration and 

(vii)    pandemic response applications and projects funded by the US government or other US public source

  
 3 

 “FDA” means the United States Food and Drug Administration or any successor
agency thereto. 
 “Field of Use” means Development and commercialization of a Product for subcutaneous administration
based on the SenseCore Technology, in the Exclusive Areas. 
 “Generic” or “Generics” means a drug or
biologic which is no longer subject to patent or regulatory exclusivity. 
 “Improvement” means any invention or discovery
that is conceived or first reduced to practice during performance of the Development activities, whether invented or discovered solely by scPharma, solely by Sensile or jointly by scPharma and Sensile. 

“Intellectual Property Rights” means (i) Patent Rights, (ii) Know-How,
(iii) rights associated with Know-How that are works of authorship including copyrights, copyright applications, and copyright registrations; and (iv) rights in any trade names, trademarks, service
marks, domain names, logos, trade dress and brand features. 
 “Know-How” means all
information, whether tangible or intangible and whether patentable or not patentable, including inventions, technologies, know-how, research and formulation methods, proprietary information, processes,
procedures, techniques, algorithms, programs, discoveries, improvements, devices, pharmaceuticals, biologics, products, concepts, designs, prototypes, samples, ideas, models, technical information, materials, drawings, specifications, trade secrets,
data and results. 
 “Laws” means all applicable laws, regulations, rules or orders. 

“NDA” means a New Drug Application submitted to the FDA in the United States in accordance with the United States Federal
Food, Drug and Cosmetic Act, as amended, and the rules and regulations promulgated thereunder, with respect to a pharmaceutical product. 

“Net Sales” shall mean the gross amount received by scPharma or its Affiliate from a Third Party for the applicable Product,
less the following; 
 (a)    the cost of the applicable Device and other fees paid by scPharma to Sensile; 

(b)    any payment (including, but not limited to, royalties or other license fees) to one or more Third Parties to
obtain a patent license in the absence of which scPharma could not legally make, import, use, sell, or offer for sale the Product that includes the applicable Device; 

(c)    customary trade, quantity, or cash discounts to the extent actually allowed and taken; 

(d)    amounts repaid or credited by reason of rejection or return; 

(e)    any taxes or other governmental charges levied on the production, sale, transportation, delivery, or use of a
Product which is paid by or on behalf of scPharma; and 

  
 4 

 (f)    outbound transportation and distribution costs prepaid or allowed and
costs of insurance in transit. 
 “Patent Rights” shall mean (i) all patents and patent applications in any country or
supranational jurisdiction; and (ii) any provisionals, substitutions, divisions, continuations, continuations in part, reissues, renewals, registrations, confirmations, reexaminations, extensions, supplementary protection certificates and the
like, of any such patents or patent applications. 
 “Pre-Existing Intellectual
Property” shall mean any and all Intellectual Property Rights existing as of March 18,2013. 
 “Product”
means a combined product consisting of a Drug and a Device. 
 “Pump” means the disposable rotary-piston pump developed and
owned or controlled by Sensile for use in the Device. 
 “Regulatory Approval” means the approvals, licenses,
registrations, or authorizations granted or issued by any national, regional, state or local governmental entities and agencies, necessary for the development, registration, manufacture, use, transport, export, import, promotion or sale of the
Product in a country, including pricing and reimbursement approvals to the extent the applicable regulatory authorities in such country require a pricing or reimbursement approval prior to commercialization of a Product in such country. 

“Regulatory Authority” means any applicable regulatory and/or governmental body or bodies having jurisdiction over a Drug,
the Device or the Product in the Territory. 
 “Reusable Component” shall mean a device component comprised of the motor,
battery, electronics for operations and other components, that is designed to be (i) combined with the Disposable Component and (ii) suitable for multiple Drug administration when used with the Disposable Component. 

“scPharma Inventions” shall mean all Intellectual Property Rights comprising or in, to or that claim or Cover any and all
(a) Products, (b) components of any and all Products, (c) Drugs, and (d) Improvements of any and all of the foregoing, in each case, which result or arise from the Development activities (including in the development, testing or
manufacture of any of the foregoing), whether by Sensile or scPharma, or their respective personnel or subcontractors, jointly or individually. scPharma Inventions do not include any technology specifically described under Sensile Inventions. 

“SenseCore Technology” means the Intellectual Property Rights Covering the Pump. 

“Sensile Inventions” means all Intellectual Property Rights comprising or in, to, or that claim or Cover (a) the Device,
(b) manufacturing processes for the Device, and (c) Improvements of any and all of the foregoing, in each case, which result or arise from the Development activities, whether by Sensile or scPharma, or their respective personnel or
subcontractors, jointly or individually and which are not specific to the Device, including without limitation the patents listed on Schedule 1.1. 

  
 5 

 “Sensile Pre-Existing Intellectual
Property” means Pre-Existing Intellectual Property, owned or Controlled by Sensile Med, Sensile Holding or Sensile Patent, including the Intellectual Property Rights listed on
Schedule 1.2. 
 “Supply Cost” means the cost of the applicable Device and other fees paid
by scPharma to Sensile and/or to other manufactures of the Device and/or its components. 
 “Term” means as defined in
Section 10 below. 
 “Territory” means worldwide. 

“Third Party” means any party other than Sensile, scPharma and their respective 

2.    LICENSE 

2.1    Exclusive License Grant, During the Term and subject to the terms of this Agreement, Sensile hereby grants
and agrees to grant to scPharma an exclusive (even as to Sensile), worldwide license, with a limited right to sublicense (as described below), under the Sensile Pre-Existing Intellectual Property and Sensile
Inventions, to use, have used, Develop, have Developed, sell, offer for sale, import and export the Products, Devices and subsequent modifications, enhancements, improvements or versions thereof in the Field of Use, including to perform the
Development activities required to commercialize Products in the Field of Use (the “License”). 

2.2    Manufacturing License Grant. In the event scPharma engages itself or an alternative supplier, effective upon
the date of notice delivered to Sensile by scPharma therefor (“Alternative Supplier Notice”), Sensile hereby grants and agrees to grant to scPharma an exclusive, worldwide license, with a limited right to sublicense (as described
below), under the Sensile Pre-Existing Intellectual Property and Sensile Inventions to make or have made Products, Devices and subsequent modifications, enhancements, improvements or versions thereof in the Field of Use (“Manufacturing
License”). The Manufacturing License shall become part of the License on the date of the Alternative Supplier Notice. Sensile shall have the right to approve each alternative supplier, which approval shall not be unreasonably withheld or
delayed. Sensile shall provide such alternative supplier with sufficient information to permit such alternative supplier to manufacture the Device, and shall exercise best efforts to support the manufacture of the Device by such supplier. [***].

 2.3    Sublicensing. Sensile hereby grants and agrees to grant to scPharma, subject to these limitations, the
exclusive right to sublicense its rights under the License to make, have made, sell, offer for sale, import and export Products, Devices and subsequent modifications, enhancements, improvements or versions thereof by an Affiliate or Third Party
manufacturer or distributor, in each case, on behalf of scPharma, in the Field of Use (License and such right to sublicense, the “Exclusive License”). 

2.4    Exclusivity. The continuation of exclusivity in the Exclusive License shall be subject to
Section 2.6. In the event additional exclusive fields are added in accordance with Section 2.7, the License shall be exclusive as agreed by the Parties for such Additional Field (defined below), and the definitions of
Exclusive Areas and Field of Use shall be deemed to include such, additional exclusive fields. 

  
 6 

 2.5    No Implied Licenses. Except as expressly set forth in this
Agreement, neither Party shall be deemed to have granted to the other Party (by implication, estoppel or otherwise), any other licenses, rights, title, or interest in or to any other Intellectual Property Rights Controlled by a Party. 

2.6    Exclusivity Lapses. Exclusivity of the License shall be subject to the achievement of the following
milestones. At all times, Sensile shall work diligently with scPharma to Develop and commercialize Products and Devices in the Field of Use. In the event of a delay in the Development timelines attributable to Sensile or factors outside of
scPharma’s control, the Parties will work together in good faith to adjust such timelines and corresponding milestones. In the event that any of these milestones are not met, scPharma will have [***] after the applicable milestone to submit a
written plan to Sensile for the achievement of such milestone. scPharma and Sensile will negotiate in good faith for up to [***] the plan for the achievement of the milestone. If scPharma does not achieve the milestone by the end of such [***]
negotiation period or, if later, the date on which the Parties agree in writing, only Sensile shall have the right to determine the following: That the exclusivity of the Exclusive License shall lapse with respect to the applicable country or
territory and the applicable Exclusive Area and such portion of the Exclusive License shall become non-exclusive, in each case effective upon receipt by scPharma of a notice (the “Conversion
Notice”) therefor. Such expiration of exclusivity shall not affect scPharma’s right, and Sensile’s obligation to work with scPharma, under this Agreement and the Original Agreements to research and develop any Device, and the
Parties will continue to research and develop such Device in accordance with the terms and conditions of this Agreement and the applicable Development Plan. Exclusivity of the License shall lapse on an Exclusive Area-by-Exclusive Area basis in accordance with the following terms. 

(a)    Loop Diuretics Exclusivity. The License shall convert from an exclusive license to a non-exclusive license in the field of loop diuretics in the event scPharma does not meet the following milestones: 

(i)    the filing with the FDA of an NDA, as appropriate, or filing with the appropriate Regulatory
Authority in the European Union of a similar application or filing (including a CE marking application), in either case for a Product in the field of loop diuretics [***]; 

(ii)    the first commercial sale in the United States or European Union, as applicable, of a Product
within [***] after Regulatory Approval for sales of a Product in the field of loop diuretics in the United States or European Union; provided, however, that if such milestone is not achieved, only exclusivity in the applicable country or geographic
territory in which the milestone was not achieved shall expire; 
 (iii)    [***]; 

(iv)    the failure to file an NDA or CE mark application in the United States or European Union (each a
“Major Market Territory”), as applicable, within [***] after first commercial sale of the applicable Product in the first Major Market Territory for which such an application was filed pursuant to clause (i) above; provided,
however, that if such milestone is not achieved, only exclusivity in the applicable country or geographic territory for which the applicable application has not been filed shall expire, 

  
 7 

 (v)    for countries outside the United States and European
Union, the failure to initiate a regulatory filing within [***] after the first commercial sale of the applicable Product in the United States; provided, however, that if such milestone is not achieved, only exclusivity in the country or territory
for which a regulatory filing was not initiated shall expire; and 
 (vi)    the failure of the FDA to
approve the Product within [***] after filing the applicable NDA; provided however, that if such milestone is not achieved, only exclusivity in the United States shall expire. 

2.7    Additional Fields. 

(a)    From time to time scPharma may wish to Develop or commercialize a drug-device combination based on an existing
Device for subcutaneous administration based on the SenseCore Technology in fields outside the then-current Field of Use, excluding the Excluded Field (“Additional Field”). In that event, scPharma will provide Sensile written notice
of its intentions and the applicable Additional Field. Sensile will respond to such notice within [***] to: (i) if Sensile has an alternate business interest pertaining to a drug/device combination that would preclude scPharma’s
development and commercialization plan, Sensile shall so inform scPharma, or (ii) if Sensile does not have such an interest, Sensile will send scPharma a notice of acceptance (“Notice of Acceptance”) and grant scPharma a
period of exclusive evaluation and negotiation for [***], during which Sensile and its Affiliates will cooperate in good faith with scPharma with respect to the evaluation of the intended Product. In the event that the Development of any such
Product requires additional Development activities, the Parties shall negotiate in good faith a Development Plan for such Product within [***] of the date of the Notice of Acceptance from Sensile and negotiate in good faith reasonable and customary
Development charges that may apply. Any such Product shall be subject to the Per-Unit Fee set forth in Section 3.1(a). 

(b)    In the event scPharma desires exclusivity for such Product and/or in an Additional Field, scPharma will notify
Sensile in writing the scope of the desired exclusivity (such notice, the “Additional Field Notice”), Such exclusivity may be defined by the applicable Drug, the Drug class, the intended use, or a therapeutic area. If such
exclusivity is requested by scPharma, scPharma’s notice will contain certain milestones required to maintain such exclusivity. Such milestones may relate to [***]. Sensile shall respond to such exclusivity request within [***] with acceptance
or denial of the request for exclusivity. In the event Sensile accepts such request by written notice to scPharma (the “Exclusivity Acceptance Notice”), scPharma shall pay Sensile a royalty on Net Sales of such Product as set forth
in Section 3 below. For each Additional Field granted to scPharma exclusively, the Incremental Disposable Units volume established in Exhibit 2.6(a) will be added to the Minimum Volumes. The following example is to clarify
the aggregate minimum volumes: [***]. 
 (c)    In the event scPharma has not requested exclusivity by means of an
Additional Field Notice, Sensile may elect to grant scPharma exclusivity for the class of therapeutic agents to which the Product belongs, in exchange a royalty on Net Sales of such Product as set forth in Section 3 below. 

3.    FEES AND PAYMENT 

3.1    Consideration. 

  
 8 

 (a)    Per-Unit Fee. scPharma
will pay Sensile the per unit prices set forth in Schedule 3.1(a) for each Reusable Component and Disposable Component included in a product sold to a Third Party or used in clinical trials (the “Reusable Component Per-Unit Fee” and “Disposable Component Per-Unit Fee,” respectively, and collectively, the “Per-Unit
Fee”) For avoidance of doubt, no Per-Unit Fee is payable for units used in release testing or for samples. 

(b)    Royalty on Net Sales. scPharma will pay Sensile a [***] royalty on Net Sales of Products. In the event the
exclusivity lapses under Section 2.6 or Sensile materially breaches an obligation (including with respect to scPharma’s ability to maintain exclusivity), then with respect to the countr(y)/(ies) or Product(s) for which scPharma no
longer has exclusivity, all royalty obligations shall immediately cease. 
 3.2    Sales Reports. Within [***] of
the end of each calendar quarter, scPharma shall deliver to Sensile a report setting forth, for such calendar quarter, the following information, on a
Product-by-Product, country-by-country and Territory-wide basis: (a) Net
Sales of each Product, (b) units sold of each Product, (c) the Per-Unit Price due for the sale of Products, (d) the royalty payment due hereunder, and (e) the basis for
any adjustments to the royalty payment or Per-Unit Prices payable for such calendar quarter. The total royalty and Per-Unit Price due for the sale of all such Products
during such calendar quarter shall be remitted [***]. 
 3.3    Royalty Terms. The obligation to pay royalties
under this Agreement shall be imposed only once with respect to any sale of any Product to end users/distributors, and shall not attach with respect to any intra-company transfers between scPharma Affiliates. With respect to any particular Product
in any particular country, scPharma shall only be obligated to pay royalties during the period during which the sale, offer for sale or importation of such Product in such country would infringe, but for the license granted herein, a valid claim in
a Patent Right included in the Sensile Pre-Existing Intellectual Property or Sensile Inventions covering such Product in such country. 

3.4    Payments. Late payments for amounts that are not the subject of a good faith dispute shall accrue interest
[***]. All payments due hereunder to Sensile shall be made in United States Dollars, and are exclusive of all sales, use, value added, withholding and other taxes and duties. Payments will be made via wire transfer to the account specified by
Sensile in writing from time to time, 
 3.5    Books and Records. scPharma shall keep books and accounts of
record in connection with the sale of Products in sufficient detail to permit accurate determination of all figures necessary for verification of royalties to be paid hereunder. scPharma shall maintain such records for a period of [***] after the
end of the calendar quarter in which they were generated. All reports and financial information of scPharma shall be deemed to be scPharma’s Confidential Information and subject to the provisions of Section 4. 

3.6    Audit Right. Upon [***] prior written notice, a public accounting firm engaged by Sensile and to which
scPharma has no reasonable objection shall have the right to inspect the books of account, records, documents and instruments of scPharma related to the sales of Products [***], at any time during regular business hours during the term of this
Agreement to ascertain the accuracy of such records; provided, however, that such audits may not be performed by Sensile more than once per calendar year and that Sensile shall not be permitted to audit the same period of time more
than once. Such accountant, prior to any 

  
 9 

 
review hereunder, shall have entered into an appropriate confidentiality agreement with scPharma and shall have been instructed not to reveal to Sensile the details of its review information
presented in a summary fashion as is necessary to report the accountant’s conclusions to Sensile. The calculation of all amounts with respect to each calendar quarter shall be binding and conclusive upon both Parties [***] after the close of
said quarter. [***] 
 4.    CONFIDENTIALITY 

4.1    Confidentiality Obligations. The Receiving Party acknowledges that it will have access to the Disclosing
Party’s Confidential Information. The Receiving Party agrees that it will not (a) use any such Confidential Information in any way, for its own account or the account of any Third Party, except for the exercise of its rights and
performance of its obligations under this Agreement, or (b) disclose any such Confidential Information to any person or entity, other than furnishing such Confidential Information to (i) its employees, contractors and
consultants who are required to have access to the Confidential Information in connection with the exercise of Receiving Party’s rights or performance of its obligations under this Agreement and (ii) its accountants and advisors who
have a “need-to-know” for the purpose of providing services to such Party; provided, however, any and all of the above-described
employees, contractors, consultants and advisers are bound by written agreements or, in the case of attorneys or other professional advisers, formal ethical duties, requiring to treat, hold and maintain such Confidential Information in accordance
with the terms and conditions of this Section 4 or for the purpose of evaluating the applicable investment, loan or acquisition. The Receiving Party agrees that it will not allow any unauthorized person access to the
Disclosing Party’s Confidential Information, and that the Receiving Party will take all action reasonably necessary to protect the confidentiality of such Confidential Information, including implementing and enforcing procedures to minimize the
possibility of unauthorized use or copying of such Confidential Information. 
 4.2    Disclosures Required by
Law. In the event the disclosure of the Disclosing Party’s Confidential Information is required by applicable law, judicial or regulatory subpoena, Receiving Party shall provide Disclosing Party with prompt written notice of any such
requirement in order to afford Disclosing Party time either to seek an appropriate protective order (or other remedy) or a waiver of compliance therewith. If such order or other remedy is not obtained, Receiving Party shall disclose only that
portion of the applicable Confidential Information that, in the opinion of counsel to such Party, is legally required to be disclosed and shall exercise all reasonable efforts to obtain assurances that confidential treatment will be accorded the
applicable information. Receiving Party shall cooperate reasonably with Disclosing Party in all respects in seeking to obtain a protective order or other remedy or otherwise to diligently contest or limit the required disclosure. 

4.3    Terms of this Agreement. 

(a)    Confidentiality. Neither Party will disclose any of the terms of this Agreement to any Third Party without
the prior written consent of the other Party. Notwithstanding the foregoing, either Party may disclose such terms: 

(i)    to (A) its accountants and advisors who have a “need-to-know” for the purpose of providing services to such Party and (B) existing and potential investors, lenders, acquirers, collaboration and/or
co-development partners, distributors, reseller, licensees and the accountants and advisors of any of the foregoing; provided that any such recipient under either of the foregoing clauses (A) or
(B) is bound by a 

  
 10 

 
written agreement (or in the case of attorneys or other professional advisors, formal ethical duties) requiring such recipient to treat, hold and maintain the terms of this Agreement on a
confidential basis, and 
 (ii)    in order to comply with an applicable judicial process, if in the
reasonable opinion of such Party’s counsel, such disclosure is necessary for such compliance, provided that such Party shall notify the other Party of such Party’s intent to make any such disclosure sufficiently prior to making such
disclosure so as to allow such other Party adequate time to review and comment on such disclosure and further to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed. 

(b)    Legal and Regulatory Requirements. This Agreement and terms hereof may be disclosed as otherwise
required pursuant to applicable law, regulation, stock market or stock exchange rule or rule of a self-regulatory organization (e.g., rules or regulations of the United States Securities and Exchange Commission, the NASDAQ or the NYSE); provided
that a Party proposing to make such a disclosure as required by law, rule or regulation shall inform the other Party a reasonable time prior to such required disclosure, shall provide the other Party with a copy of the text of such proposed
disclosure sufficiently in advance of the proposed disclosure to afford such other Party a reasonable opportunity to review and comment upon the proposed disclosure (including, if applicable, the redacted version of this Agreement) and shall
reasonably consider, consistent with applicable law, rule and regulation (including interpretations thereof), the requests of the other Party regarding confidential treatment for such disclosure. Without limiting any of the foregoing, the filing
Party shall request confidential treatment of sensitive provisions of the Agreement to the extent permitted by applicable laws and as reasonably practicable. 

5.    REPRESENTATIONS, WARRANTIES AND COVENANTS 

5.1    Authority. Each Party represents, warrants and covenants to the other Party that (a) it has all
requisite power and authority (corporate and otherwise) to enter into this Agreement and this Agreement has been duly and validly executed and delivered by it; (b) all necessary consents, approvals and authorizations of all government
authorities and other persons required will be obtained by the Effective Date in connection with the execution, delivery and performance of this Agreement; (c) its execution and delivery of this Agreement and the performance of its
obligations hereunder do not and will not conflict with, or result in a breach of, or a default under, its organizational instruments or any other agreement, instrument, order, or law applicable to it or by which it may be bound. 

5.2    Intellectual Property. Sensile represents, wan-ants and covenants to
scPharma that, with respect to any Intellectual Property subject to this Agreement, (a) there is no claim, suit, proceeding, or other investigation pending, nor to the actual knowledge of such Party, overtly threatened, which is likely
to prevent or materially interfere with such Party’s timely performance under this Agreement, (b) it is the sole and exclusive owner of the Sensile Pre-Existing Intellectual Property and Sensile
Inventions, all of which is free and clear of any claims, liens, charges or encumbrances, (c) it has the right to grant the licenses granted herein, and this Agreement, including the grant of the licenses herein, shall not violate or breach any
other existing obligation of Sensile to any Third Party. Sensile represents, warrants and covenants to scPharma that, to the best of its knowledge, the Sensile Pre-Existing Intellectual Property and Sensile
Inventions are subsisting, valid and enforceable in each jurisdiction in which presently pending. Sensile’s employees and subcontractors have executed, or will 

  
 11 

 
execute, prior to performing any activities under the Development Plan or otherwise performing services contemplated by or exercising rights or fulfilling obligations on behalf of Sensile under
this Agreement, written intellectual property assignment and confidentiality and nondisclosure agreements sufficient to enable each Party to exercise its respective rights and comply with its respective intellectual property and confidentiality
obligations under this Agreement. In particular, Sensile Patent AG represents and warrants that it owns the rights, title, and interest in the Sensile Pre-Existing Intellectual Property and Sensile Inventions
based on each inventor either (A) having been an employee of Sensile Medical AG at the time of conception and production of the invention disclosed and/or claimed in the one or more Licensed Patents on the basis that the invention was made in
the course of their work for Sensile Medical AG and in performance of their contractual obligations, and Sensile Medical AG having then assigned all rights, title, and interest in the Licensed Patents to Sensile Patent AG via a valid assignment
agreement, or (B) or having assigned all rights, title, and interests of the one or more Licensed Patents on which that inventor is named to Ecole Polytechnique Federale De Lausanne (EPFL) of Lausanne, Switzerland, and EPFL having then
assigned all rights, title, and interest in the Licensed Patents to Sensile Patent AG via a valid assignment agreement. 

5.3    Third Party Licenses. Without limitation to any other representation, warranty or covenant, Sensile
represents, warrants and covenants that, as needed and reasonably feasible, Sensile shall seek out a license, at no cost to scPharma, to ensure the unencumbered use of the Device by scPharma. 

5.4    Disclaimer. EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR
IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE. NEITHER PARTY WARRANTS THAT THE RESULTS OF THE DEVELOPMENT ACTIVITIES OR THE DEVICE WILL BE
IN ACCORDANCE WITH THE EXPECTATIONS OF THE OTHER PARTY OR WILL PRODUCE OR RESULT IN THE DESIRED END PRODUCT, THAT THE DEVICE WILL BE SAFE, EFFECTIVE, OR COMMERCIALLY VIABLE, OR THAT THE DEVICE WILL BE APPROVED BY ANY REGULATORY AUTHORITY. THE
FOREGOING DISCLAIMER SHALL APPLY EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH WARRANTY, AND NOTWITHSTANDING THE FAILURE OF THE ESSENTIAL PURPOSE OF SUCH WARRANTY. 

6.    OWNERSHIP OF INVENTIONS AND INTELLECTUAL PROPERTY RIGHTS 

6.1    Ownership. 

(a)    Inventions. Each Party’s ownership of Pre-Existing
Intellectual Property is not affected by this Agreement, and neither Party shall have any claims to or rights in any Pre-existing Intellectual Property of the other Party, except as expressly provided for in this Section 6. Sensile shall
be the sole owner of Sensile Inventions, and scPharma shall be the sole owner of scPharma Inventions, The Parties agree to promptly and fully disclose any and all scPharma Inventions and Sensile Inventions to each other in writing. To the extent
scPharma has any rights in Sensile Inventions, scPharma hereby assigns and agrees to assign to Sensile all of its Intellectual Property and proprietary rights, title and interest in and to Sensile Inventions; and all rights of action and claims for
damages and benefits arising due to past and present infringement of said rights. To the extent Sensile has any rights in the scPharma Inventions, Sensile hereby assigns and agrees to assign to scPharma all of its Intellectual Property and
proprietary rights, title and interest in and to the scPharma Inventions; and all rights of action and claims for damages and benefits arising due to past and present infringement of said rights. 

  
 12 

 (b)    Clinical Trial Results. With the exception of Sensile
Inventions in the Clinical Trial Results (defined below), notwithstanding anything to the contrary in any of the Original Agreements, to the extent allowable under applicable law, scPharma shall own all right, title and interest in and to the data,
results, discoveries, material, methods, processes, knowledge, know-how, experience, patentable or non-patentable inventions, technology and information of any type whatsoever arising from, or discovered or reduced to practice within the framework
of, conducting a Clinical Trial (“Clinical Trial Results”). “Clinical Trial Results” further means any and all tangible forms, which embody or contain the Clinical Trial Results. The Clinical Trial Results shall deemed to
be Confidential Information proprietary to scPharma. Notwithstanding anything to the contrary in any of the Original Agreements, scPharma shall have no obligation to share any portion of the Clinical Trial Results with Sensile Med or Sensile
Holding. For the avoidance of doubt, Sensile shall have1 no right, title or interest in or to the Clinical Trial Results. 

(c)    Molds, Tools and Equipment. Notwithstanding anything to the contrary in the Original Agreements, scPharma
shall be the owner of all molds, tools, and equipment designed specifically for the making of each Device. 

(d)    Molds, tools, and equipment related to the manufacturing of the SenseCore pump components (Pump shaft and Pump
housing) shall not be changed or modified without the explicit consent of Sensile, which consent shall not be unreasonably withheld, delayed or conditioned. 

(e)    Use of Devices in Marketing. Prototypes, Devices and Device components developed under this Agreements for
scPharma may be of value to Sensile in its marketing and business development activities with third parties outside the Exclusive Field. Subject to availability after meeting customer demand, Sensile may request from scPharma permission for the use
of up to [***] selected from Prototypes, Devices, and Device components (“Marketing Devices”) for its marketing and business development purposes outside the Exclusive Field, which permission will not be unreasonably withheld,
delayed or conditioned. Sensile may not sell Marketing Devices for commercial purposes in any field. All use of Marketing Devices shall be subject to scPharma’s Intellectual Property rights and ownership of molds, specifications, drawings, and
blueprints for the Device. For avoidance of doubt, Sensile shall not have the right, and shall not communicate to others that it has the right, to utilize scPharma’s molds, specifications, drawings or blueprints, or scPharma’s Intellectual
Property Rights, to manufacture the Device or Product for a Third Party, in any field. Sensile may disclose to Third Parties design drawings and the identify of materials used, but no other information regarding the Product or Device or any
component thereof. Sensile will pay scPharma the same PER-UNIT FEES, in addition to applying the production costs per device, as described in SCHEDULE 3.1(a) to this agreement for all Marketing
Devices 
 6.2    Prosecution. 

(a)    Sensile shall have the sole right to file, prosecute, and maintain Patent Rights with respect to Sensile’s Pre-Existing Intellectual Property and Sensile Inventions, and all costs and expenses associated therewith shall be borne by Sensile. scPharma shall have the sole right to file, prosecute, and maintain Patent Rights
with respect to scPharma’s Pre-Existing Intellectual Property and scPharma Inventions, and all costs and expenses 

  
 13 

 
associated therewith shall be borne by scPharma. Each Party agrees to cooperate and assist the other Parry to execute, and shall cause its personnel to execute, all documents reasonably necessary
for the other Party to secure, perfect, effectuate and preserve such Party’s ownership rights in and to their respective inventions. Sensile shall consult with and keep scPharma informed of all substantive issues relating to the preparation,
filing, prosecution and maintenance of the Sensile Pre-Existing Intellectual Property and Sensile Inventions, and shall furnish to scPharma copies of documents relevant to such preparation, filing, prosecution
or maintenance in sufficient time prior to filing such document to allow for review and comment by scPharma. Sensile shall consider scPharma’s comments in good faith and, to the extent possible in the reasonable exercise of its discretion,
shall incorporate all such comments. In the event that Sensile does not incorporate any such comment, it shall contact scPharma to discuss and resolve any disagreement thereto in good faith. 

(b)    Sensile shall not file any application for a Patent Right that claims or Covers a combination of Sensile’s Pre-Existing Intellectual Property or Sensile Inventions with a pharmaceutical product related to a Drug in the Field of Use or in a field for which scPharma has sent an Additional Field Notice for any existing and
agreed upon future Products (“Combination Intellectual Property”). 
 (c)    scPharma shall not file
any application for a Patent Right that claims or Covers Sensile Pre-Existing Intellectual Property or Sensile Inventions without prior approval by Sensile, which shall not be unreasonably withheld,
conditioned or delayed. Notwithstanding, this Section 6.2(c) shall not prevent scPharma from filing any Patent Right application that claims or Covers a drug-device combination. In the event that, after the Effective Date,
(i) scPharma files a Patent Right application that claims or covers a drug-device combination, and (ii) a Patent Right issues to scPharma from such Patent Right application that, absent a license from scPharma, would prevent
Sensile from making, using, selling or offering for sale any Sensile Pre-Existing Intellectual Property or Sensile Inventions, then scPharma shall grant Sensile a perpetual, royalty-free license under such
Patent Right solely to the extent that such a license is required to make, use, sell, offer to sell and import Devices and only in the Excluded Field for such country where such patent was issued. For purposes of clarity, such license shall not
extend to the Field of Use or any therapeutic area or field where scPharma has exclusivity to the Sensile Pre-Existing Intellectual Property or Sensile Inventions. 

(d)    During the term of this Agreement, Sensile and its Affiliates will not disclose the Device Master Record
(“DMR”) to any Third Party without permission of scPharma. 
 6.3    Enforcement. 

(a)    [***]. Each of the Parties shall notify the other Party within [***] if they become aware of any such Infringement
Action. [***]. The Party commencing legal action (the “Defending Party”) shall, unless otherwise agreed in writing, [***]. The Defending Party shall consider in good faith requests and comments by the other Party. 

(b)    Each Party will cooperate in all reasonable respects with the Defending Party. The Defending Party may prosecute
or defend an Infringement Action in its own name or, if required by applicable law, in the name of another Party and may join such other Party as a party to the Infringement Action if a court of competent jurisdiction determines that such Party is
an indispensable party to such Infringement Action, in each case, [***]. Each Party hereby irrevocably and unconditionally waives any objection to such joinder, including on 

  
 14 

 
grounds of personal jurisdiction, venue or forum non conveniens. Where the Defending Party brings an Infringement Action in the name of another Party or joins another Party, the Defending Party
may not settle those proceedings or agree to any order, injunction, settlement or other binding obligation that prohibits or restricts that named or joined Party in any way without the prior written consent of that named or joined Party. 

(c)    Any proceeds received from an Infringement Action shall first be applied to reimburse legal fees of the respective
Parties in proportion to the costs and expenses incurred. [***]. 
 7.    TECHNOLOGY ESCROW 

7.1    Within [***] of the date of signing this Agreement, the parties shall enter into a technology escrow agreement
(“Escrow Agreement”) with a mutually acceptable escrow agent (“Escrow Agent”). Within [***] of the execution of said Escrow Agreement, Sensile shall deposit with the Escrow Agent: (a) executed
authorization letters in the form set forth in Exhibit 7.1 for each subcontractor and vendor it uses in the manufacture or design of the Device, (b) a copy of the design history file for each Device, (c) a copy of
the device master record for each Device, (d) specifications for each Device, and (e) designs for molds, tools, and any other equipment designed specifically for the manufacture of a Device or any component thereof (the
“Deposit”). Sensile shall update the Deposit on [***] basis, and shall deposit additional authorization letters each time it engages a new subcontractor or vendor, and each time an existing subcontractor or vendor begins work on a
new Device. Sensile shall retain, or cause its subcontractors or vendors to retain, a copy of all documents included in the Deposit for its records. The Escrow Agreement shall instruct the Escrow Agent to: (1) not return the Deposit, or
any part thereof to Sensile, without obtaining the prior written consent of scPharma; (ii) designate scPharma as the sole and exclusive beneficiary, along with any successors or assigns of scPharma, as confirmed in writing by scPharma,
and (iii) notify scPharma when deposits have been received. scPharma shall pay all costs and fees associated with the escrow account when due and payable. The following events shall constitute a release event under the Escrow Agreement
and shall immediately entitle scPharma to request from the Escrow Agent, and the Escrow Agent to release to scPharma, the Deposit: (i) Sensile notifies Escrow Agent to release the Deposit to scPharma; (ii) Sensile materially
breaches this Agreement and fails to cure such breach; (iii) Sensile notifies scPharma that it no longer has the capacity to make Devices; (iv) Sensile has been unable to meet its supply obligations for [***];
(v) Termination for Insolvency of Sensile; or (vi) or Sensile commits more than [***] of a material obligation in a period of [***] (each, a “Release Event”). In the event of a Release Event, scPharma shall
promptly notify the Escrow Agent to release the Deposit and Sensile shall execute all documents and provide all assistance required for the Escrow Agent to effect such release, promptly after requested to do so. Sensile shall not enter into any
definitive agreement with an Escrow Agent regarding the Deposit without prior review and written approval of the execution version of such agreement by scPharma. 

7.2    Sensile shall ensure that any subcontractor or vendor it uses under this Agreement (or generally in the manufacture
or design of the Device): (a) shall be obligated to assist in any technology transfers contemplated in this Agreement in the manner set forth herein, (b) shall timely effect such technology transfers, and (c) shall accept the
assignment of such subcontractor’s or vendor’s contract to scPharma upon any transfer authorized by the parties’ agreements. For the avoidance of doubt, scPharma shall continue to be obligated to pay royalties per the terms of this
Agreement (and subject to the termination provisions of such agreement) following a Release Event. 

  
 15 

 8.    INDEMNIFICATION 

8.1    Indemnification by Sensile. Sensile shall defend, indemnify, and hold harmless scPharma, its Affiliates and
their respective officers, directors, employees, and agents (“Representatives”) from and against any and all claims, losses, demands, causes of action, and all related costs and expenses of every kind (including reasonable
attorneys’ fees, costs, and expenses) occurring, growing out of, incident to, or resulting directly or indirectly from a Third Party claim based on: (a) Sensile’s fraud, willful or intentional acts or gross negligence;
(b) Sensile’s grossly negligent design or manufacture of products; (c) infringement of an Intellectual Property Right of a Third Party resulting from product design, features, or manufacturing processes developed by
Sensile; (d) Sensile’s breach of a material obligation under this Agreement; and (e) Sensile’s failure to comply with applicable laws, in each case except for those losses for which scPharma has an obligation to
indemnify Sensile, as to which losses each Party will indemnify the other to the extent of their respective liability for the losses. 

8.2    Indemnification by scPharma. Except as otherwise provided in Section 8.1 above, scPharma
shall defend, indemnify, and hold harmless Sensile, its Affiliates and their respective Representatives from and against any and all claims, losses, demands, causes of action, and all related costs and expenses of every kind (including reasonable
attorneys’ fees, costs, and expenses) occurring, growing out of, incident to, or resulting directly or indirectly from a Third Party claim based on: (a) scPharma’s fraud, willful or intentional acts or gross negligence;
(b) scPharma’s breach of a material obligation under this Agreement; and (c) scPharma’s failure to comply with applicable laws, in each case except for those losses for which Sensile has an obligation to indemnify
scPharma, as to which losses each Party will indemnify the other to the extent of their respective liability for the losses. 

8.3    Conditions of Indemnity. 

(a)    The Parry claiming a right of indemnification or defense under this Agreement shall provide the indemnifying Party
prompt written notice (in all events within [***] of any such claim, including a copy thereof, served upon it, and shall cooperate fully with the indemnifying Party and its legal representatives in the investigation of any such claim, at the
indemnifying Party’s expense. 
 (b)    The indemnifying Party shall have the right to exercise sole control over
the defense and settlement of any such claim, including the sole right to select defense counsel and to direct the defense or settlement of any such claim; provided that the indemnifying Party shall not enter into any
non-monetary settlement or admit fault or liability on the indemnified Parry’s behalf without the prior written consent of the indemnified Party, which consent shall not be unreasonably withheld, delayed
or conditioned. Notwithstanding the foregoing, if the indemnified Party is advised by counsel that there may be a conflict between the positions of the indemnifying Party and the indemnified Party in conducting the defense of such action, then the
indemnified Party may elect to conduct the defense to the extent reasonably determined by such counsel to be necessary to protect the interests of the indemnified Party, at the expense of the Indemnifying Party, if it is determined by agreement of
the indemnifying Party and the indemnified Party, or by a court of competent jurisdiction, that the indemnified Party is entitled to indemnification hereunder. If the indemnifying Party elects not to assume the defense of such claim or action, the
indemnifying Party shall reimburse the indemnified Party for the reasonable legal fees and expenses incurred and shall be bound by the results obtained by the indemnified Party in respect of such claim or action if it is determined by agreement of
the indemnifying Party and the indemnified Party or by a court of competent 

  
 16 

 
jurisdiction that the indemnified Party is entitled to indemnification hereunder; provided, however, that no such claim or action shall be settled without the written consent of the indemnifying
Party. Without limiting the foregoing, the indemnified Party shall have the right to select and to obtain representation by separate legal counsel, and except as provided for above, all costs and expenses incurred by the indemnified Party for such
separate legal counsel shall be borne by the indemnified Party. 
 (c)    Either Party shall be relieved of any
indemnification obligation hereunder if the indemnified Party either [***]. 
 9.    LIMITATION OF LIABILITY 

EXCEPT FOR LIABILITY FOR A BREACH OF [***] OR A BREACH OF [***] OR [***] AND EACH PARTY’S INDEMNITY OBLIGATIONS FOR
CLAIMS ASSERTED BY THIRD PARTIES, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ITS AFFILIATES FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL DAMAGES, INCLUDING ANY CLAIMS FOR DAMAGES BASED UPON LOST PROFITS RELATING TO THIS AGREEMENT, EVEN IF
SUCH PARTY HAS BEEN INFORMED IN ADVANCE OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT FOR LIABILITY FOR A BREACH OF [***] OR A BREACH OF [***] OR [***] AND EACH PARTY’S INDEMNITY OBLIGATIONS FOR CLAIMS ASSERTED BY THIRD
PARTIES, EACH PARTY’S AGGREGATE LIABILITY TO THE OTHER PARTY FOR ANY CLAIM RELATED TO, OR IN CONNECTION WITH, THIS AGREEMENT, OR THE PRODUCT (WHETHER TN CONTRACT, TORT, NEGLIGENCE, STRICT LIABILITY, BY STATUTE OR OTHERWISE) SHALL BE LIMITED TO
AN AMOUNT EQUAL TO THE TOTAL PAYMENTS BY SCPHARMA TO SENSILE UNDER THIS AGREEMENT. 
 In no event shall a party’s liability to the
other party for direct or indirect damages exceed $[***] for a single event or aggregate related events (aggregate event limit). 

10.    TERM AND TERMINATION 

10.1    Term. This Agreement shall commence on the Effective Date and extend until terminated as set forth in this
Agreement (the “Term”). 
 10.2    Termination for Business Reasons. This Agreement may be
terminated for any reason by scPharma, including scPharma’s decision not to continue development of a Product or failure of a Product to receive approval from the appropriate Regulatory Authority, upon [***] prior written notice to Sensile,
Upon receipt of notice of termination from scPharma, Sensile shall use its best efforts to limit or terminate any outstanding financial commitments for which scPharma will be held responsible within [***] of termination by scPharma. For any
termination pursuant to this Section 10.2, scPharma shall reimburse Sensile for all costs incurred by it for work performed by Sensile prior to the effective date, of termination, including all
non-cancellable obligations. Payments under this Section 10.2 shall be subject to Section 2 hereof. 

10.3    Termination for Material Breach. Either Party shall have the right to terminate this Agreement upon written
notice to the other Party if, after receiving written notice of such material breach, the other Party fails to cure such breach within [***] from the date of such notice. 

  
 17 

 10.4    Termination for Insolvency. A Party may terminate this
Agreement upon bankruptcy, insolvency, dissolution or winding up of the other Party (“Termination for Insolvency”). 

(a)    In the event of Termination for Insolvency of Sensile, (i) the applicable escrow agent will release to
scPharma the authorization letters and other deposits made in accordance with the Escrow Agreement and (ii) Sensile shall, upon request by scPharma, transfer to scPharma or cause to transfer to scPharma all works in progress, completed
Devices and components thereof, all Sensile Pre-Existing Intellectual Property and Sensile Inventions necessary for scPharma to continue to manufacture the Products in according with the applicable specifications. If this Agreement is terminated
under any applicable insolvency law or Sensile or an administrator refuses to further perform this Agreement (or any of Sensile’s obligations hereunder) under any applicable bankruptcy or insolvency law, then scPharma may elect to retain all of
its license rights under this Agreement (including the rights described in this Section 10.4). All rights and licenses granted under or pursuant to this Agreement by ether Party are, and shall otherwise be deemed to be, for purposes of
Section 365(n) of the United States Bankruptcy Code (the “Bankruptcy Code”), licenses of rights to “intellectual property” as defined under Section 101 of the Bankruptcy Code. The Parties agree that
the scPharma, as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code. 

(b)    In the event of Termination for Insolvency of scPharma, all obligations of Sensile to scPharma under this
Agreement, including any licenses granted by Sensile to scPharma shall immediately terminate. scPharma shall reimburse Sensile for all costs incurred by it for work performed by Sensile prior to the effective date of termination, including all non-cancellable obligations. 
 10.5    Rights and Duties Upon Termination.
Upon termination of the Agreement, Sensile and scPharma will cooperate to provide for an orderly termination of the Development Plan. Upon notice of termination of this Agreement, the Parties agree to use reasonable efforts to minimize further
costs. Each Party shall also promptly return all Confidential Information of the other Party in its custody or control. Termination of this Agreement shall not affect any other rights or remedies which may be available to either Party at law or in
equity. 
 10.6    Survival of Provisions. In addition to any provisions that by their nature survive expiration
or termination of this Agreement, the duty of scPharma to pay accrued but unpaid fees and Sections 1 (Definitions), 3.5 (Books and Records), 4 (Confidentiality), 5 (Representations, Warranties and Covenants),
6.1 (Ownership of Inventions, 8 (Indemnification), 9 (Limitation of Liability), 10.5 (Rights and Duties upon Termination), 10.6 (Survival of Provisions) and 11 (Miscellaneous) shall survive the
termination or expiration of this Agreement for any reason. Section 7.1 shall survive termination for Insolvency of Sensile or termination for Sensile’s material breach, for so long as is necessary for the Escrow Agent to receive
instructions and complete the release following a Release Event. For the purpose of clarification, the following sections will not survive the termination of this agreement: Section 2 (License), except pursuant to
Section 10.4(a). 
 11.    MISCELLANEOUS 

11.1    Independent Contractors. The relationship between Sensile and scPharma is that of independent contractors
and nothing herein shall be deemed to constitute 

  
 18 

 
the relationship of partners, joint venturers, or principal and agent between Sensile and scPharma. Neither Party shall have any express or implied right or authority to assume or create any
obligations on behalf of or in the name of the other Party or to bind the other Party to any contract, agreement, or undertaking with any Third Party. 

11.2    Assignment; Subcontracting. scPharma may assign this Agreement, or assign or delegate any rights or
obligations under this Agreement, without Sensile’s consent. Sensile may not assign this Agreement, or assign or delegate its rights or obligations under this Agreement, without the prior written consent of scPharma (which shall not be
unreasonably withheld, conditioned, or delayed), provided, however, that (a) Sensile may assign this Agreement without the prior written consent of scPharma to an Affiliate or in the event of a sale of all or substantially all of such
Party’s assets or business. Any permitted assignee shall assume all obligations of its assignor under this Agreement. No assignment shall relieve either Party of its responsibility for the performance of any obligation that accrued prior to the
effective date of such assignment. This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective permitted successors and assigns. Any attempted sale, pledge, assignment, sublicense or other transfer in
violation of this Section 11.2 shall be void and of no force or effect. 
 11.3    Waiver. No failure
or delay on the part of the Parties hereto to exercise any right, power, or privilege hereunder or under any instrument executed pursuant hereto shall operate as a waiver; nor shall any single or partial exercise of any right, power or privilege
preclude any other or further exercise thereof or the exercise of any other right, power or privilege, 

11.4    Severability. If any provision or part of this Agreement is declared invalid by any court of competent
jurisdiction or a government agency having jurisdiction, such invalidity shall not affect the remainder of the provision or the other provisions of the Agreement, which shall remain in full force and effect. 

11.5    Publication; Use of Name. Neither Party shall issue any press release, publicity or other form of public
written disclosure related to this Agreement, the activities conducted hereunder, or the other Party without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned, or delayed. Except as otherwise
required by, or in the good faith determination by a Party, complies with, Law or securities disclosure rules or guidance, or as required by the terms of this Agreement or mutually agreed upon by the Parties, neither Party shall make any use of the
name of the other Party in any advertising or promotional material, or otherwise, without the prior written consent of the other Party. 

11.6    Further Assurances. Each Party agrees to duly execute and deliver, or cause to be duly executed and
delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in
connection with this Agreement or to carry out more effectively the provisions and purposes, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

11.7    Construction. Unless the context otherwise requires, (a) “or” is not exclusive,
(b) words in the singular include the plural, and words in the plural include the singular, (c) “herein,” “hereof and other words of similar import refer to this Agreement, and

  
 19 

 
(d) “including” and “includes,” when following any general provision, sentence, clause, statement, term or matter, shall be deemed to be followed by % but not limited
to,” and “, but is not limited to,” respectively. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any
ambiguity in this Agreement shall be construed against the drafter shall not apply. 
 11.8    Non-Solicitation. During the term of this Agreement and for a period of [***] thereafter, scPharma shall not, and shall require that its Affiliates do not, directly or indirectly solicit, engage or hire any
employee or contractor of Sensile or its Affiliates; provided, however, that nothing herein shall prohibit scPharma from soliciting for employment, hiring or employing any person who responds to a general solicitation or advertisement in a
newspaper, on the internet, or in some similar medium so long as such general solicitation or advertisement is not directed at any individual employee or group of employees of Sensile or its Affiliates. 

11.9    Notices. Any notices under this Agreement shall be in writing as registered mail and delivered to the
Parties at the postal addresses set forth below, or to the postal address subsequently provided by a Party in accordance with this Section 11.9, by (a) first class certified mail, return receipt requested, with notice deemed given
upon receipt; (b) a nationally-recognized overnight courier service, with notice deemed given on the date of receipt as indicated on the courier’s receipt, or (c) pdf via electronic mail: 

 

			
	if to scPharma:	  	scPharmaceuticals Inc.
		  	131 Hartwell Avenue, Suite 215
		  	Lexington, MA 02421
		  	Attention: [***]
		  	Tel: [***]
		  	Fax [***]
		  	Email address:
		
	if to Sensile:	  	Sensile Medical AG
		  	Fabrikstrasse 10
		  	CH-4614 Hägendorf
		  	Switzerland
		  	Attention: CEO
		  	Tel: [***]
		  	Fax: [***]
		  	Email address:

 The address and person provided above may be changed by either Party by providing the other Party with written notice of such
change. 
 11.10    Counterparts. This Agreement and any amendment or supplement hereto may be executed in
separate counterparts, including by facsimile or electronic signature, each of which shall be deemed to be an original, and all of which taken together shall constitute one and the same instrument. 

11.11    Dispute Resolution; Governing Law. In the event of any controversy or claim arising out of or relating to
this Agreement, or a breach thereof, the Parties hereto shall consult and negotiate with each other and, recognizing their mutual interests, attempt to reach a satisfactory solution. If they do not reach settlement within a period of [***], then,
upon notice by 

  
 20 

 
any party to the other(s), any unresolved controversy or claim shall be settled by arbitration administered by the International Centre for Dispute Resolution (“ICDR”) in accordance
with the provisions of its International Arbitration Rules. The arbitration will be heard and determined by three (3) arbitrators who are retired judges or attorneys with at least seven (7) years of experience in the medical device
industry. Each Party will appoint one (1) arbitrator and the third arbitrator will be selected by the two (2) Party-appointed arbitrators, or, failing agreement within [***] following the date of receipt by the respondent of the claim, by
ICDR. The place of arbitration shall be London, England. The language of the arbitration shall be English. Except as may be required by law, neither a Party nor its representatives may disclose the existence, content, or results of any arbitration
hereunder without the prior written consent of the Parties. The arbitration award so given will be a final and binding determination of the dispute, will be fully enforceable in any court of competent jurisdiction, and will not include any damages
expressly prohibited by Section 9. Except in a proceeding to enforce the results of the arbitration or as otherwise required by law, neither Party nor any arbitrator may disclose the existence, content or results of any arbitration
hereunder without the prior written agreement of both Parties. Notwithstanding the dispute resolution procedures set forth in this Section 11.11, each Party acknowledges and agrees that breach of any of the terms or conditions of this
Agreement would cause irreparable harm and damage to the other and that such damage may not be ascertainable in money damages and that as a result thereof the non-breaching Party would be entitled to seek from
a court equitable or injunctive relief restraining any breach or future violation of the terms contained herein by the breaching Party without the necessity of proving actual damages or posting bond. Such right to equitable relief is in addition to
whatever remedies either Party may be entitled to as a matter of law or equity, including money damages. This Agreement shall be governed by and interpreted in accordance with the laws of England. 

11.12    Entire Agreement. This Agreement and the Original Agreements constitute the entire understanding of the
Parties in connection with the subject matter herein and a complete and exclusive statement of the terms of their agreement and supersede all prior and contemporaneous arrangements, agreements and understandings, both oral and written among the
Parties hereto or between any of them, including the Original Agreements. In the event of any conflict between this Agreement and the Original Agreements or any other previously executed agreement involving the parties hereto, this Agreement shall
control. This Agreement or any provision hereof shall not be amended, supplemented, or waived except in a writing signed by each of the Parties hereto. For purpose of clarification, if subjects are not defined or covered in this agreement, previous
agreements, such as the Partnership Agreement and the Omnibus Amendment are still valid. 
 [Remainder of the page intentionally left
blank] 

  
 21 

 IN WITNESS WHEREOF, this Agreement has been executed by the duly authorized
representatives of the Parties hereto as of the Effective Date. 
  

					
	scPHARMACEUTICALS INC.	  		  	SENSILE HOLDING AG
			
	 /s/ Pieter Muntendam
	  		  	 /s/ Benno Zehnder

	Signature	  		  	Signature
			
	 Pieter Muntendam
	  		  	 Benno Zehnder

	Name	  		  	Name
			
	 President
	  		  	 Member of the Board

	Title	  		  	Title
			
	SENSILE MEDICAL AG	  		  	SENSILE PATENT AG
			
	 /s/ Derek Brandt
	  		  	 /s/ E. Conradi

	Signature	  		  	Signature
			
	 Derek Brandt
	  		  	 E. Conradi

	 Name
	  		  	 Name

			
	 CEO
	  		  	 Chairman of the Board

	Title	  		  	Title

  
 22 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 
 SCHEDULE 1.1 

SENSILE INVENTIONS 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 
 SCHEDULE 1.2 

SENSILE PRE-EXISTING INTELLECTUAL PROPERTY 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

 EXHIBIT 2.6(a) 

Minimum Device Unit Volumes 
  

																	
	 Minimum Volume Calculation
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 Minimum Disposable Units
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 Incremental Disposable Units Per Additional Field
	  		  		  		  		  		  		  		  	
	 following Regulatory Approval
	  	[***]	  	[***]	  	[***]	  		  		  		  		  	
	 Incremental Disposable Units
	  	[***]	  	[***]	  	[***]	  		  		  		  		  	

 SCHEDULE 3.1(a) 

PER-UNIT FEES 

REUSABLE COMPONENT PER-UNIT FEES 

[***] per unit 
 DISPOSABLE COMPONENT PER-UNIT FEES 
 [***] per unit 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

FIRST AMENDMENT TO LICENSE AGREEMENT 

This FIRST AMENDMENT TO LICENSE AGREEMENT (this “First Amendment”) is made and entered into this day of June 29,
2016 (the “First Amendment Effective Date”) by and among scPharmaceuticals Inc., having an address at 131 Hartwell Avenue, Suite 215, Lexington, MA 02421 (“scPharma”) and Sensile Medical AG
(“Sensile Med”) and Sensile Pat AG (“Sensile Pat”), both having an address at Fabrikstrasse 10, CH-4614 Hägendorf, Switzerland and Sensile Holding AG (“Sensile
Holding”), having an address at Zugerstrasse 76b, CH-6340, Baar, Switzerland (Sensile Med, Sensile Holding and Sensile Pat together in any combination, “Sensile”) (each of scPharma,
Sensile Med, Sensile Holding and Sensile Pat, a “Party” and, collectively, the “Parties”). All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the License Agreement
(defined below). 
 RECITALS 

WHEREAS, the Parties entered into that certain License Agreement, dated June 29, 2015, (the “License Agreement”)
pursuant to which scPharma licensed certain products owned by Sensile to perform development activities required to commercialize such products; and 

WHEREAS, the Parties wish to amend the License Agreement by modifying the exclusivity provisions, technology escrow and certain other
terms. 
 NOW, THEREFORE, in consideration of the premises and mutual agreements and covenants set forth in this Amendment,
the Parties have agreed as follows: 
 AGREEMENT 

1.1    Section 2.6(a)(i) of the License Agreement is hereby amended by deleting the date
“[***]” and replacing it with “[***]”. 
 1.2    The first sentence in
Section 7.1 is hereby deleted in its entirety and replaced with the following language: 
 “During the term of
this Agreement, either Party may request a technology escrow by notifying the other Party in writing. Within [***] of delivery of such notice, the Parties shall enter into a technology escrow agreement (“Escrow Agreement”) with a
mutually acceptable escrow agent (“Escrow Agent”).” 

1.3    Exhibit 2.6(a) is hereby deleted in its entirety and replaced with the amended
Exhibit 2.6(a) attached hereto. 
 [Signatures follow on next page] 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this First
Amendment to be executed by their respective authorized representatives. 
  

					
	ScPHARMACEUTICALS INC.	 		  	SENSILE HOLDING AG
			
	 /s/ Pieter Muntendam
	 		  	 /s/ E. Conradi

	Signature	 		  	Signature
			
	 Pieter Muntendam
	 		  	 Erwin Conradi

	Name	 		  	Name
			
	 President
	 		  	 President of the Board of Directors

	Title	 		  	Title
			
	SENSILE MEDICAL AG	 		  	SENSILE PAT AG
			
	 /s/ Derek Brandt     /s/ Lars Birkmann
	 		  	 /s/ E. Conradi

	Signature	 		  	Signature
			
	 Derek Brandt     Lars Birkmann
	 		  	 Erwin Conradi

	Name	 		  	Name
			
	 CEO
                 Head BS
	 		  	 President of the Board of Directors

	Title	 		  	Title

 Signature Page to First Amendment 

 EXHIBIT 2.6(a) 

Minimum Disposable Component Unit Volumes (amended) 
  

															
	Minimum Volume Calculation	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
								
	Minimum Disposable Units	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
								
	Incremental Disposable Units per Additional Field	  		  		  		  		  		  		  	
								
	   following Regulatory Approval
	  	[***]	  	[***]	  	[***]	  		  		  		  	
								
	 Incremental Disposable Units
	  	[***]	  	[***]	  	[***]	  		  		  		  	

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

Amendment #2 
 To
License Agreement 
 This Amendment #2 (“Amendment #2”), dated August 5, 2016 (“Amendment Effective
Date”), to the License Agreement dated June 29, 2015 (the “Agreement”), is by and among scPharmaceuticals Inc. (“scPharma”) and Sensile Medical AG, Sensile Holding AG and Sensile Patent AG
(“Sensile”). 
 Unless defined herein, words used in this Amendment #2 as defined terms shall have the same meanings herein
as in the Agreement. 
 RECITALS 

WHEREAS, scPharma and Sensile each desire to amend the terms of the Agreement as described in this Amendment; and 

NOW, THEREFORE, in consideration of the mutual covenants, promises and agreements herein contained, the Parties hereto agree as
follows: 
 1.    Section 6.3 (a). Section 6.3(a) of the Agreement is deleted in its entirety and
replaced with the following amended 6.3(a): 
 “6.3 Enforcement. [***]. Each of the Parties shall notify the other Party within
[***] if they become aware of any such Infringement Action. [***]. The Party commencing legal action (the “Defending Party”) shall, unless otherwise agreed in writing, [***]. The Defending Party shall consider in good faith requests
and comments by the other Party.” 
 2.    Effectiveness of Agreement and Amendment #2. Except as expressly
provided herein, nothing in this Amendment #2 shall be deemed to waive or modify any of the provisions of the Agreement, which otherwise remains in full force and effect. In the event of any conflict between the Agreement and this Amendment #2, this
Amendment #2 shall prevail with respect to the subject matter hereof. 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment #2 as of the Amendment
Effective Date. 
  

									
	scPharmaceuticals Inc.	  		 	Sensile Medical AG
					
	By:	  	 /s/ Pieter Muntendam
	  		 	By:	 	 /s/ E. Conradi /s/ Lars Birkmann

					
	Name:	  	 Pieter Muntendam
	  		 	Name:	 	 E. Conradi Lars Birkmann

					
	Title:	  	 President
	  		 	Title:	 	 Chairman Head of Business Support

					
	Date:	  	 7/29/2016
	  		 	Date:	 	 5/8/2016    5/8/2016

			
	Sensile Patent AG	  		 	Sensile Holding AG
					
	By:	  	 /s/ E. Conradi
	  		 	By:	 	 /s/ E. Conradi

					
	Name:	  	 E. Conradi
	  		 	Name:	 	 E. Conradi

					
	Title:	  	 Chairman
	  		 	Title:	 	 Chairman

					
	Date:	  	 5/8/2016
	  		 	Date:	 	 5/8/2016

  
 2 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

THIRD AMENDMENT TO LICENSE AGREEMENT 

This THIRD AMENDMENT TO LICENSE AGREEMENT (this “Third Amendment”) is made and entered into this 22 day of November,
2016 (the “Third Amendment Effective Date”) by and among scPharmaceuticals Inc., having an address at 131 Hartwell Avenue, Suite 215, Lexington, MA 02421 (“scPharma”) and Sensile Medical AG, having an address at
Fabrikstrasse 10, CH-4614 Hägendorf, Switzerland (“Sensile Med”) and Sensile Holding AG (“Sensile Holding”) and Sensile Patent AG (“Sensile Patent”),
both having an address at Zuger Strasse 76b, CH-6340, Baar, Switzerland (Sensile Med, Sensile Holding and Sensile Patent together in any combination, “Sensile”) (each of scPharma, Sensile Med,
Sensile Holding and Sensile Patent, a “Party” and, collectively, the “Parties”). All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the License Agreement (defined below).

 RECITALS 

WHEREAS, the parties entered into that certain License Agreement dated June 29, 2015, as amended by that First Amendment to
License Agreement dated June 29, 2016 and that Second Amendment to Non-Exclusive License Agreement dated August 5, 2016 (as amended, the “License Agreement”) pursuant to which
scPharma licensed certain products owned by Sensile to perform development activities required to commercialize such products; and 

WHEREAS, the Parties wish to amend the License Agreement by modifying the exclusivity provisions therein. 

NOW, THEREFORE, in consideration of the premises and mutual agreements and covenants set forth in this Amendment, the Parties have
agreed as follows: 
 AGREEMENT 

1.1    Section 2.6(a)(i) of the License Agreement is hereby amended by deleting the date “[***]” and replacing it with
“[***]”. 
 [Signatures follow on next page] 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this Third
Amendment to be executed by their respective authorized representatives. 
  

					
	ScPHARMACEUTICALS INC.	 		 	SENSILE HOLDING AG 
			
	 /s/ Pieter Muntendam
	 		 	 /s/ E. Conradi

	Signature	 		 	Signature
			
	 Pieter Muntendam
	 		 	 Conradi, Erwin

	Name	 		 	Name
			
	 President and CEO
	 		 	 President

	Title	 		 	Title
			
	SENSILE MEDICAL AG 	 		 	SENSILE PATENT AG
			
	 /s/ Derek Brandt
	 		 	 /s/ E. Conradi

	Signature	 		 	Signature
			
	 Derek Brandt
	 		 	 Conradi, Erwin

	Name	 		 	Name
			
	 CEO
	 		 	 President

	 Title
	 		 	Title

 /s/ Sandra de Haan 
 Sandra de
Haan 
 Head BD 

  
 2 

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

FOURTH AMENDMENT TO LICENSE AGREEMENT 

This FOURTH AMENDMENT TO LICENSE AGREEMENT (this “Fourth Amendment”) is made and entered into this 25th day of February, 2017 (the “Fourth Amendment Effective Date”) by and among scPharmaceuticals Inc., having an address at 131 Hartwell Avenue, Suite 215, Lexington, MA 02421
(“scPharma’”) and Sensile Medical AG, having an address at Fabrikstrasse 10, CH-4614 Hägendorf, Switzerland (“Sensile Med”) and Sensile Holding AG (“Sensile
Holding”) and Sensile Patent AG (“Sensile Patent”), both having an address at Zuger Strasse 76b, CH-6340, Baar, Switzerland (Sensile Med, Sensile Holding and Sensile Patent together
in any combination, “Sensile”) (each of scPharma, Sensile Med, Sensile Holding and Sensile Patent, a “Party” and, collectively, the “Parties”). All capitalized terms not otherwise defined herein
shall have the meanings ascribed to them in the License Agreement (defined below). 
 RECITALS 

WHEREAS, the Parties entered into that certain License Agreement dated June 29, 2015 as amended by that First Amendment to License
Agreement dated June 29, 2016, that Second Amendment to Non-Exclusive License Agreement dated August 5, 2016 and that Third Amendment to License Agreement dated November 22, 2016 (as amended,
the “License Agreement”) pursuant to which scPharma licensed certain products owned by Sensile to perform development activities required to commercialize such products; and 

WHEREAS, the Parties wish to amend the License Agreement by modifying the terms as set forth herein. 

NOW, THEREFORE, in consideration of the premises and mutual agreements and covenants set forth in this Amendment, the Parties
have agreed as follows: 
 AGREEMENT 

1.1    Section 2.6(a)(i) of the License Agreement is hereby amended by deleting the date
“[***]” and replacing it with “[***]”. 
 1.2    Exhibit 2.6(a) is hereby
deleted in its entirety and replaced with the amended Exhibit 2.6(a) attached hereto. 
 [Signatures follow on next
page] 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this Fourth
Amendment to be executed by their respective authorized representatives. 
  

					
	 ScPHARMACEUTICALS INC.
	 		  	 SENSILE HOLDING AG

			
	 /s/ John Tucker
	 		  	 /s/ E. Conradi

	Signature	 		  	Signature
			
	 John Tucker
	 		  	 Conradi, E.

	Name	 		  	Name
			
	 CEO
	 		  	 President

	Title	 		  	Title
			
	 SENSILE MEDICAL AG
	 		  	 SENSILE PATENT AG

			
	 /s/ Derek Brandt
	 		  	 /s/ E. Conradi

	Signature	 		  	Signature
			
	 Derek Brandt
	 		  	 Conradi, E.

	Name	 		  	Name
			
	 CEO
	 		  	 President

	Title	 		  	Title

 Signature Page to First Amendment 

 EXHIBIT 2.6(a) 

Minimum Disposable Component Unit Volumes (amended) 

Minimum Volume Calculation 

													
	 following Regulatory Approval of furosemide
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 Minimum Disposable Units
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	
	Incremental Disposable Units per Additional Field
	 following Regulatory Approval
	  	[***]	  	[***]	  	[***]	  		  		  	
	 Incremental Disposable Units
	  	[***]	  	[***]	  	[***]	  		  		  	

 For purposes of this Exhibit 2.6(a), “Year 1” means the period beginning on the date
of the applicable Regulatory Approval and ending one (1) year after Regulatory Approval. “Year 2” means the second year after such Regulatory Approval (i.e., the one-year period following
Year 1), “Year 3” means the third year after such Regulatory Approval, and so on.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]